CA2044746C - Polypeptide compound and a process for preparation thereof - Google Patents

Polypeptide compound and a process for preparation thereof Download PDF

Info

Publication number
CA2044746C
CA2044746C CA002044746A CA2044746A CA2044746C CA 2044746 C CA2044746 C CA 2044746C CA 002044746 A CA002044746 A CA 002044746A CA 2044746 A CA2044746 A CA 2044746A CA 2044746 C CA2044746 C CA 2044746C
Authority
CA
Canada
Prior art keywords
alkoxy
compound
alkanoyl
salt
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002044746A
Other languages
French (fr)
Other versions
CA2044746A1 (en
Inventor
Toshiro Iwamoto
Akihiko Fujie
Kumiko Nitta
Yasuhisa Tsurumi
Nobuharu Shigematsu
Chiyoshi Kasahara
Motohiro Hino
Masakuni Okuhara
Kazuo Sakane
Kohji Kawabata
Hidenori Ohki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909013558A external-priority patent/GB9013558D0/en
Priority claimed from GB909023666A external-priority patent/GB9023666D0/en
Priority claimed from GB919101552A external-priority patent/GB9101552D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CA2044746A1 publication Critical patent/CA2044746A1/en
Application granted granted Critical
Publication of CA2044746C publication Critical patent/CA2044746C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Polypeptide compounds of the following general formula (see formula I) wherein R1 is hydrogen or acyl group, R2 is hydroxy or acyloxy, R3 is hydrogen or hydroxysulfonyloxy, and R4 is hydrogen or carbamoyl, with proviso that (i) R2 is acyloxy, when R3 is hydrogen, and (ii) R1 is not palmitoyl, when R2 is hydroxy, R3 is hydroxysulfonyloxy and R4 is carbamoyl, and pharmaceutically acceptable salts thereof. Also disclosed are the preparation of these compounds, pharmaceutical compositions containing same, and the treatment of infectious diseases using these compounds. These compounds are particularly active against a number of pathogenic microorganisms in humans and animals.

Description

NEW POLYPEPTIDE COMPOUND AND
A PROCESS FOR PREPARATION THEREOF
The present invention relates to new polypeptide compound and a pharmaceutically acceptable salt thereof.
Mare particularly, it relates to new polypeptide compound and a pharmaceutically acceptable salt thereof, which have antimicrobial activities iespecially antifungal activities), to a process for preparation thereof, to pharmaceutical compositian comprising the same, and to a method fox treating or preventing infectious diseases in human being or animals.
Accordingly, one object of the present invention is to provide the polypeptide compound and a pharmaceutically acceptable salt thereof, which are highly active against a number of pathogenic microorganisms in human being and animals.
Another object of the present invention is to provide a process for the preparation of the polypeptide compound and a salt thereof.
A further object of the present invention is to _ 2 _ provide a pharmaceutical composition comprising, as an active ingredient, said polypeptide compound or a pharmaceutically acceptable salt thereof.
Still further object of the present invention is to provide a method for treating or preventing infectious diseases caused by pathogenic microorganisms, which comprises administering said polypeptide compound to human being or animals.
The object polypeptide compound of the present invention is novel and can be represented by the following general formula [I] .
HO OH

~

4 ~~ CH
R -H C 0 ~ 3 2 0 N~ LI]
2 o Ho rrH~~ off ~OH

~2 wherein R1 is hydrogen or acyl group, R2 is hydroxy or acyloxy, R3 is hydrogen or hydroxysulfonyloxy, and R4 is hydrogen or carbamoyl, with proviso that (i) R2 is acyloxy, when R3 is hydrogen, and (ii) R1 is not palmitoyl, when R2 is hydro~y, R3 is hydroxysulfonyloxg and R'~ is carbamoyl.

~~~ ~~~t) The palypeptide compound CI] of the present invention can be prepared by the processes as illustrated in the follawing schemes.
Process 1 HO OH HO OH
. HO 0 HO 0 NH NH
H3C NHCO(CH2)14CH3 H3C

HN OH
0 H 0 elimination 0 H 0 HN OH
-g o ~~ .reaction of H2N N 3 H N 0 ~~3 0 N-acyl group 2 0 N
H0 ~1'f~" OH HO yNH OH
101 off 0 i ' ~ _ off 0 Ho-s-o ~ / Ho-s-o ll Il [IIa [Ia]
or a salt thereof or a salt thereof Process 2 Ho off HO OH
HO o H3C N 0 2 i H3C NH_Ra 0 H 0 ~ ~ 0 H 0 HN OH
acylation ~
0 d/ \
n H2N 0 N 3 reaction H N 0 ~~3 3 0 HO ~~~ OH ~ 2 0 N
HO ~~~~' OH
~OH 0 0 _ 0H 0 HO-S-0 ~ / HO-S-0 I II

HO
35 [Ia] [Ib]
or a salt thereof or a salt thereof Process 3 Ho OH
HO OH
~ HO 0 , HO 0 _ 1 H3C N ~ ~ elimination H3C NH-R~
0 H 0 HN OH reaction of N HN~ OH

0 ~3 amino , H
HZN N protective H N 0 ~~3 HO 0 NH OH group 2 HO 0 NH N OH
0 . 0 II ._' OH ~ 0 OH 0 HO-S-0 ~ ~ , Ho-S-0 II il 0 HO i 0 HO
[Ic] jId]
or a salt thereof or a salt thereof Process 4 HO OH r ' HO OH

NH . HO 0 H C ~_R1 Pyridinethione 3 N 0 d which may have HgC

' 0 H 0 higher alkyl N 0 HN OH
CH [III) 0 H
CH
H N 0~ 3 i 0~ 3 0 N or a salt ;g2N " N
HO ~~~ OH thereof ' HO 0 ' NH OH
0 ~ 0 3 0 I I OH 0 off 0 HO-S-0 II -' II ~ ~ HO-S-0 [Ie) [If) or a salt thereof or a salt thereof 2~~~'~~~
y'/','l,lpCC r1 HO OH HO OH

NH HH
H3C ~-R~ ' H3G NH-R
Hq N\.0 HN OH acylation Hq N'0 HH OH
R4-H ~ 0 ~~3 reaction t, ~~ 0 HO HH OH HO tTH ~" OH.
2 0 ~f~ R -H2C 0 N
'0H 0 _ ~ ~OH 0 R3 ~ / R3 ~
H~ Ra ~ [IVl . [Igl or a salt thereof or a salt thereof wherein R3 and R4 are each as defined above, Ra is acyl group exclusive of palmitoyl, Rb is ar(lower)alkanoyl which has higher alkoxy and protected amino, R~ is ar(lower)alkanoyl which has higher alkoxy and amino, Ra is halo(lower)alkanoyl, Re is pyridylthio(lower)alkanoyl which may have higher alkyl, Rf is acyl group, Ra is acyloxy, and R5 is acyl group.
~'he starting compound flll or a salt thereof is novel and can be prepared by the following fermentation process.

t Drnneae 2f A strain belonging Ho off to the Coleophoma Ho 0 which is capable fermentation NH
H3C ~ NHCO(CH2)14CH3 of producing the . N 0 compound [II] or 0 H 0 HN OH
a salt thereof ,~
A N 0 ~~3 ~ Ho ~ ~ off 0 _ OOH 0 I I
HO-S-0 ~
II

HO
[II]
or a salt thereof Some of the starting compound [IV] are novel and can be prepared according to the aforesaid Process 1 to 4.
Suitable pharmaceutically acceptable salt of the object compound [I] is conventional non-toxic mono or di salts and include a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and an alkaline earth metal salt [e. g. calcium salt, magnesium salt, ete.], an ammonium salt, an organic base salt [e. g.
trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N-dibenzylethylenediamine salt, ete.] an organic acid addition salt [e. g. formate, acetate, trifluroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.], an inorganic acid additian salt [e. g. hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, etc.], a salt with an amino acid [e. g. arginine salt, aspartic acid salt, glutamic acid salt, etc.], and - ~~~~'~~~~
the like.
In the above and subsequent description of this specification, suitable examples of the various S definitions axe explained in detail as follows :
The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.
The term "higher" is intended to mean 7 to 20 carbon atoms, unless otherwise indicated.
Suitable "acyl group" may be aliphatic acyl, aromatic acyl, heterocyclic acyl, arylaliphatic acyl and heterocyclic-aliphatic acyl derived from carboxylic acid, carbonic acid, carbamic acid, sulfonic acid, and the like.
Suitable example of the "acyl group" thus explained may be lower alkanoyl [e.g~. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, pivaloyl, etc.]
which may have one or more (preferably 1 to 3) suitable substituent(s) such as halogen (e. g. f luoro, chloro, 2?0 bromo, iodo); aryl (e. g. phenyl, naphthyl, anthryl, etc.) which may have one or more (preferably 1 to 3) suitable substituent(s) like hydroxy, higher alkoxy as explained below, aforesaid aryl, or the like; lower alkoxy as explained below; amino; protected amino, preferably, acylamino such as lower alkoxycarbonylamino (e. g.
methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino, t-butoxycarbanylamino, pentyloxycarbonylamino, hexyloxycarbonylamino, etc.); or the like;
di(lower)alkylamino (e. g. dimethylamino, N-methylethylamino, diethylamino, N-propylbutylamino, dipentylamino, dihexylamino, etc.); lower alkoxyimino (e. g. methoxyimino, ethoxyimino, propoxyimino, butoxyimino, t-butoxyimino, pentyloxyimino, hexyloxyimino, etc.); ar(lower)alkoxyimino such as - 2~~~'~~~i phenyl(lower)alkoxyimino (e. g. benzyloxyimino, phenethyloxyimino, benzhydryloxyimino, etc.) which may have one or more (preferably 1 to 3) suitable substituent(s) like higher alkoxy as explained below, or the like; heterocyclicthio, preferably, pyridylthio, which may have one or more (preferably 1 to 3) suitable substituent(s) like higher alkyl (e. g. heptyl, octyl, 2-ethylhexyl, nonyl, decyl, 3,7-dimethyloctyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, 3-methyl-10-ethyldodecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, icosyl, etc.), or the like;
heterocyclic group (e. g. thienyl, imidazolyl, pyrazolyl, furyl, tetrazolyl, thiazolyl, thiadiazolyl, etc.) which may have one or more (preferably 1 to 3) suitable 25 substituent(s) like amino, aforesaid protected amino, aforesaid higher alkyl, or the like; or the like;
higher alkanoyl [e. g. heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, palmitoyl, 10,12-dimethyltetradecanoyl, heptadecanoyl, stearoyl; nonadecanoyl, icosanoyl, etc.];
lower alkenoyl [e. g. acryloyl, methacryloyl, crotonoyl, 3-pentenoyl, 5-hexenoyl, etc.] which may have one or more (preferably 1 to 3) suitable substituent(s) such as aforesaid aryl which may have one or more (preferably 1 to 3) suitable substituent(s) like higher alkoxy as explained below, or the like, or the like;
'higher alkenoyl [e. g. 4-heptenoyl, 3-octenoyl, 3,6-decadienoyl, 3,7,11-trimethyl-2,6,10-dodecatrienoyl, 4,10-heptadecadienoyl, etc.];
lower alknxycarbonyl [e. g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxy-carbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.];
higher alkoxycarbonyl [e. g. heptyloxycarbonyl, actyloxycarbonyl, 2-ethylhexyloxycarbonyl, nonyloxycarbanyl, decyloxycarbonyl, - ~~~4~~
3,7-dimethyloctyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, tridecyloxycarbonyl, tetradecyloxycarbonyl, pentadecyloxycarbonyl, 3-methyl-10-ethyldodecyloxycarbonyl, hexadecyloxycarbonyl, heptadecyloxycarbonyl, octadecyloxycarbonyl, nonadecyloxycarbonyl, icosyloxycarbonyl, etc.];
aryloxycarbonyl [e. g. phenoxycarbonyl, naphthyloxycarbonyl, etc.];
arylglyoxyloyl [e. g. phenylglyoxyloyl, naphthylglyoxyloyl, etc.];
ar(lower)alkoxycarbonyl which may have one or more suitable substituent(s) such as phenyl(lower)alkoxy-carbonyl which may have nitro or lower alkoxy [e. g.
benzyloxycarbonyl, phenethyloxycarbonyl, p-nitrobenzyloxy-carbonyl, p-methoxybenzyloxycarbonyl, ete.];
lower alkylsulfonyl [e. g. methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, pentylsulfonyl, butylsulfonyl, etc.];
arylsulfonyl [e. g. phenylsulfonyl, naphthylsulfonyl, etc.] which may have one or more (preferably 1 to 3) suitable substituent(s) such as lower alkyl as explained below, higher alkoxy as explained below, or the like;
ar(lower)alkylsulfonyl such as phenyl(lower)alkylsulfonyl [e. g. benzylsulfonyl, phenethylsulfonyl, benzhydrylsulfonyl, etc.], or the like;
aroyl [e. g. benzoyl, naphthoyl, anthrylcarbonyl, .etc.] which may have one or more (preferably 1 to 5) suitable substituent(s) such as aforesaid halogen; lower alkyl (e. g, methyl, ethyl, propyl, butyl, t-butyl, pentyl, hexyl, etc.); aforesaid higher alkyl; lower alkoxy (e. g.
methoxy, ethoxy, propoxy, butoxy, t-butoxy, pentyloxy, hexyloxy, etc.) which may have one or more (preferably 1 to 10) suitable substituent(s) like aforesaid lower alkoxy, aforesaid halogen, aforesaid aryl, or the like;
higher alkoxy (e. g. heptyloxy, octylo xy, 2-ethylhexyloxy, - 1° - 2~~~'~:
nonyloxy, decyloxy, 3,7-dimethyloctyloxy, undecyloxy, dodecyloxy, tridecyloxy,.tetradecyloxy, pentadecyloxy, 3-methyl-10-ethyldodecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy, icosyloxy, etc.) which may have one or more (preferably 1 to 17) suitable substituent(s) like aforesaid halogen; higher alkenyloxy (e. g. 3-heptenyloxy, 7-octenyloxy, 2,6-octadienyloxy, 5-nonenyloxy, 1-decenyloxy, 3,7-dimethyl-6=octenyloxy, 3,7-dimethyl-2,6-octadienyloxy, 8-undecenyloxy, 3,6,8-dodecatrienyloxy, 5-tridecenyloxy, 7-tetradecenyloxy, 1,8-pentadecadienyloxy, 15-hexadecenyloxy, 11-heptadecenyloxy, 7-octadecenyloxy, 10-nonadecenyloxy, 18-icosenyloxy, etc.); carboxy;
aforesaid aryl which may have one or more (preferably 1 to 3) suitable substituent(s) like aforesaid higher alkoxy;
aryloxy (e. g. phenoxy, naphthyloxy, anthryloxy, etc.) which may have one or more (preferably 1 to 3) suitable substituent(s) like aforesaid lower alkoxy, or aforesaid higher alkoxy; or the like.
In said "acyl group", the preferred one may be lower alkanoyl; halo(lower)alkanoyl;
ar(lower)alkanoyl which may have one or more (preferably 1 to 3) hydroxy, lower alkoxy, higher alkoxy, aryl, amino, protected amino, di(lower)alkylamino, lower alkoxyimino or ar(lower)alkoxyimino which may have one or more (preferably 1 to 3) higher alkoxy;
heterocyclicthio(lower)alkanoyl which may have one or more (preferably 1 to 3) higher alkyl;
heterocyclic(lower)alkanoyl which may have one or more (preferably 1 to 3) lower alkoxyimino, higher alkyl, amino or protected amino;
ar(lower)alkoxyimino(lower)alkanoyl which may have one or more (preferably 1 to 3) higher alkoxy;
higher alkanoyl;
ar(lower)alkenoyl which may have one or mare (preferably 1 to 3) higher alkoxy;
higher alkenoyl; lower alkoxycarbonyl; higher alkoxycarbonyl; aryloxycarbonyl;
arylsulfonyl which may have one or more (preferably 1 to 3) lower alkyl or higher alkoxy;
aroyl which may have one or more (preferably 1 to 5) , halogen, lower alkyl, higher alkyl, carboxy, lower alkoxy which may have one or more (preferably 1 to ZO) halogen, lower alkoxy(lower)alkoxy, ar(lower)alkoxy, higher alkoxy which may have one or more (preferably 1 to 17) halogen, higher alkenyloxy, aryl which may have one or more (preferably 1 to 3) higher alkoxy or aryloxy which may have one or mire ( preferably 1 to 3 ) lower alkoxy or higher alko~xy ;
in which the more preferred one may be lower alkanoyl; halo(lower)alkanoyl;
phenyl(lower)alkanoyl or naphthylilower)alkanoyl, each of which may have 1 to 3 hydroxy, lower alkoxy, higher alkoxy, phenyl, amino, lower alkoxycarbonylamino, di(lowe.r)alkylamino, lower alkoxyimino, or phenyl(lower)alkoxyimino which may have 1 to 3 higher alkoxy;
pyridylthio(lower)alkanoyl which may have 1 to 3 higher alkyl;
imidazolyl(lower)alkanoyl or thiazolyl(lower)alkanoyl, each of which may have 1 to 3 lower alkoxyimino, higher alkyl, amino or lower alkoxycarbonylamino;
phenyl(lower)alkoxyimino(lower)alkanoyl which may have 1 to 3 higher alkoxy;
higher alkanoyl;
phenyl(lower)alkenoyl which may have 1 to 3 higher alkoxy;
higher alkenoyl; lower alkoxycarbonyl, higher alkoxycarbonyl; phenoxycarbonyl;
phenylsultonyl or naphthylsulfonyl, each of which may have 1 to 3 lower alkyl or higher alkoxy;
benzoyl, naphthoyl or anthrylcarbonyl, each of which may have 1 to 5 halogen, lower alkyl, higher alkyl, carboxy, lower alkoxy which may have 6 to 10 halogen, lower alkoxy(lower)alkoxy, phenyl(lower)alkoxy, higher alkoxy which may have 12 to 17 halogen, higher alkenyloxy, phenyl which may have 1 to 3 higher alkoxy, phenoxy which may have 1 to 3 lower alkoxy or higher alkoxy;
the much more preferred one may be (C1-C4)alkanoyl;
halo(C1-C4)alkanoyl;
phenyl(C1-C4)alkanoyl which may have 1 to 3 hydroxy, (C1-C~)alkoxy, (C7-C16)alkoxy, phenyl, amino, (C1-C4)alkoxycarbonylamino, di(C1-C4)alkylamino, (C1-C4)alkoxyimino or phenyl(C1-C4)alkoxyimino which may have (C7-C16)alkoxy;
naphthyl(C1-C~)alkanoyl which may have 1 to 3 (C1-C4)alkoxycarbonylamino;
1-(C7-C16)alkylpyridiniothio(C1-C4)alkanoyl;
imidazolyl(C1-C4)alkanoyl which may have 1 to 3 (C7-C16)alkyl or (C1-C4)alkoxycarbonylamino;
thiazolyl(C1-C4)alkanoyl which may have 1 to 3 (C1-C4)alkoxyimino or amino;
phenyl(C1-C4)alkoxyimino(C1-C~)alkanoyl which may have 1 to 3 (C7-C16)alkoxy;
(C7-C17)alkyl;
phenyl(C1-C~)alkenoyl which may have 1 to 3 (C7-C16)alkoxy;
(C7-C1$)alkenoyl; (C3-C6)alkoxycarbonyl;
(C7-C16)alkoxycarbonyl; phenoxycarbonyl;
phenylsulfonyl which may have (C1-C4)alkyl or (C7-C16)alkoxy;
naphthylsulfonyl which may have (C7-C16)alkoxy;
benzoyl which may have 1 to 5 halogen, (C3-C6)alkyl, (C7-C16)alkyl, carboxy, (C1-C6)alkoxy which may have 6 to 10 halogen, (C1-C4)alkoxy(C1-C4)alkoxy, phenyl(C3-C6)alkoxy, (C7-C16)alkoxy which may have 12 to 17 halogen, phenyl which may have 1 to 3 (C7-C16)alkoxy or phenoxy which may have 1 to 3 (C3-C6) alkoxy or (C~-C16)alkoxy;
naphthoyl which may have 1 to 3 (C3-C6)alkoxy, (C7-C16)alkoxy or (C7-C16)alkenyloxy;
anthrylcarbonyl;
and the most preferred one may be acetyl, 2-bromoacetyl, 2-(4-~biphenylyl)acetyl, 2-(4-octy7.oxyphenyl)acetyl, 3-(4-octyloxyphenyl)propionyl, 2-amino-2-(4-octyloxyphenyl)acetyl, 2-(t-butoxycarbonyl-amino)-2-(4-octyloxyphenyl)acetyl, 2-amino-3-(4-octyloxyphenyl)propionyl, 2-(t-butoxycarbonylamino)-3-(4-octyloxyphenyl)propionyl, 2-dimethylamino-3-(4-octyloxyphenyl)propionyl, 2-(t-butoxycarbonylamino)-2-(2-naphthyl)acetyl, 2-methoxy-2-(4-octyloxyphenyl)acetyl, 2-methoxyimino-2-(4-octyloxyphenyl)acetyl, 2-(4-oetyloxybenzyloxyimino)-2-(4-hydroxyphenyl)acetyl, 2-.(4-octyloxybenzyloxyimino)-2-phenylacetyl, 2-(4-octyloxybenzyloxyimino)acetyl, 2-(1-octyl-4-pyridinio)thioacetyl, 2-methoxyimino-2-(2-aminothiazol-4-yl)acetyl, 2-(t-butoxycarbonylamino)-3-(1-octyl-4-imidazolyl)-propionyl, 3-(4-octyloxyphenyl)acryloyl, 3,7,11-trimethyl-2,6,10-dodecatrienoyl, t-butoxycarbonyl, octyloxycarbonyl, phenoxycarbonyl, p-tolylsulfonyl, 4-octyloxyphenylsulfonyl, 6-octyloxy-2-naphthylsulfonyl, 4-(t-butyl)benzoyl, 4-octylbenzoyl, 2,3,5,6-tetrafluoro-4-(2,2,3,3,4,4,5,5-octafluoro-pentyloxy)benzoyl, 4-(2-butoxyethoxy)benzoyl, 4-(4-phenylbutoxy)benzoyl, 4-octyloxybenzoyl, 2-carboxy-4-octylnxybenzoyl, 3-methoxy-4-octyloxybenzoyl, 4-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyloxy)-2,3,5,6-tetrafluorobenzoyl, 4-(4-octyloxyphenyl)benzoyl, 4-(4-octyloxyphenoxy)benzoyl, 6-butoxy-2-naphthoyl, 2~~~~
.- 14 -6-hexyloxy-2-naphthoyl, 6-octyloxy-2-naphthoyl, 6-(2-ethylhexyloxy)-2-naphthoyl, 6-decyloxy-2-naphthoyl, 6-(3,7-dimethyloctyloxy)-2-naphthoyl, 6-dodecyloxy-2-naphthoyl, 6-(3,7-dimethyl-6-octenyloxy)-2-naphthoyl, 6-(3,7-dimethyl-2,6-octadienyloxy)-2-naphthoyl, 2-anthryl-carbonyl, 4-(~- hc~tyloxyphenyl)-benzoyl and 4-(4-hexyloxyphenoxy)benzoyl.
Suitable "acyl group exclusive of palmitoyl" can be referred to the ones as exemplified before for "acyl group" except pa7.mitoyl.
Suitable "ar(lower)alkanoyl" moiety in "ar(lower)alkanoyl which has higher alkoxy and protected amino" and "ar(lower)alkanoyl which has higher alkoxy and amino'° can be referred to the ones as exemplified before for "acyl group" and suitable examples of the substituent(s) "higher alkoxy" and "protected amino" can be referred to the ones as exemplified before for °'acyl group".
Suitable "halo(lower)alkanoyl" can be referred to the ones as exemplified before for "acyl group".
Suitable "pyridylthio(lower)alkanoyl" in "pyridylthio(lower)alkanoyl which may have higher alkyl"
can be referred to the ones as exemplified before for "aryl g:.:oup", and suitable examples of the substituent "higher alkyl" can be exemplified before for "acyl group".
Suitable "acyloxy" may include hydroxysulfonyloxy, phosphonooxy, and the like.
In the object compound [I] thus defined, the following compound [Ih] is especially preferable.

_... .._ "_.~~L,._.a..r'.~,,..b.."~'a'i:"b..uy~s'~:L~.:.:.
.::_~u_~t'a..:_.....u:.;ar.:a.;c~=~:.ty='-;:~6=-:-b-...'~°~..ir.-.--...-'...._._.._...w.,..._.._.. ,.:._.. .. . ... ..........
2~~~'~4~ y a:
HO OH

,.
H3C NH-Rl t.

0 H 0 HN OH ':
fTh]
S
H N 0 ~~3 HO ~ ~ OH

0 _ ' \OH 0 II I
HO-S-0 ~

wherein R1 is hydrogen or acyl group, with proviso that R1 is not palmitoyl.
Suitable "acylating agent" for the acylation reaction is Process 2 may be an acid compound corresponding to the aryl group to be introduced or its reactive derivative at ' the carbaxy group or a salt thereof and suitable example of said acylating agent is represented by the formula Ra - OH [V]
wherein Ra is as defined above, or its reactive derivative at the carboxy group or a salt thereof .
In the compound [V], the following compounds are novel.
R6 R~

\ /
[V-1]
or its reactive derivative at the carboxy group or a salt thereof - to -R~ cooH
R~
[V-2]
or its reactive derivative at the carboxy group or a salt thereof ~~~.~~~'~_ wherein R5 is lower alkoxy, higher alkoxy or higher alkenyloxy, R~ is -COON or -S03FI, R~ is 1 to 4 halogen, R9 is lower alkoxy which has one or more halogen, higher alkoxy which has one or more halogen.
The compounds [V-1] and [V-2] can be prepared by the ~ following processes.
Process F
HO R~ R6 R~
+ R10 _ X .-~ ~ . ~ 1'~
\ / \ i [VI] [VII] [V-1]
or a salt thereof or a salt thereof or a salt thereof 2Q~~~'~~~~~
Process C
R8 COON Rs GOOH
I + R11 - OH -s \ \

1o CvIII7 CIx7 tv-27 or a salt thereof or a salt thereof or a salt thereof wherein R6, R7, R$ and R9 are each as defined above, R10 is lower alkyl, higher alkyl or higher alkenyl, R11 is lower alkyl which has one or more halogen or higher alkyl which has one or more halogen, and X and Y are each a leaving group.
In the above definitions, suitable "lower alkoxy", "higher alkoxy","higher alkenyloxy", "halogen", "lower alkyl" and "higher alkyl°' can be referred to the ones as exemplified before.
Suitable "higher alkenyl" may include 3-heptenyl, 7-octenyl, 2,6-octadienyl, 5-nonenyl, 1-decenyl, 3,7-dimethyl-6-octenyl, 3,7-dimethyl-2,6-octadienyl, 8-undecenyl, 3,6,8-dodecatrienyl, 5-tridecenyl, 7-tetradecenyl, 1,8-pentadecadienyl, 15-hexadecenyl, 11-heptadecenyl, 7-octadecenyl, 10-nonadecenyl, 18-icosenyl and the like, in which the preferred one may be (C7-C16)alkenyl.
As for R9, "lower alhoxy" has one or mare (preferably 1 to 10, more preferably 6 to 10) halogen, and "higher alkoxy" has one or more (preferably 1 to 17, more 18 _ preferably 12 to 17) halogen.
As for R11, "lowex alkyl°' has one or more (preferably 1 to 10, more preferably 6 to 10) halogen, and "higher alkyl" has one or more (preferably 1 to.l7, more preferably 12 to 17) halogen.
As for R6, preferred "lower alkoxy" may be (C4-C6,)alkoxy.
Suitable "a leaving group" may include aforesaid halogen, lower alkanoyloxy (e. g. acetoxy, etc.), sulfonyloxy (e. g. mesyloxy, tosyloxy, etc.), and the like.
Regarding suitable salts and the reactive derivatives at the carboxy group of the compounds [V-1] and [V-2], they can be referred to the ones as exemplified below fox Z5 the compound CVI.
The reactions in Processes B and C can be carried out according to the methods disclosed later in Preparations of the present specification or the similar manners thereto.
In the compound [V], there are other novel compounds than compounds [V-1] and [V-2], and they can be prepared, for example, by the methods disclosed later in Preparations.
Suitable "pyridinethione" in Process 4 may include 1,2-dihydropyridine-2-thione, 1,4-dihydropyridine-4-thione, and the like, and said "pyridinethione" may have aforesaid "higher alkyl".
The praeesses for preparing the object compound [I]
or a salt thereof of the present invention are explained in detail in the following.

_ 1~ _ ~~~~~"~~:
Process 1 The object compound [Ia] or a salt thereof can be prepared by subjecting a compound [II] or a salt thereof to elimination reaction of N-acyl group.
This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction, reaction with an enzyme or the like.
The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
Suitable base may include an inorganic base and an organic base such as an alkali metal [e. g. sodium, potassium, etc.], an alkaline earth metal [e. g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]-undec-7-ene, or the like.
Suitable acid may include an organic acid [e. g.
formic acid, acetic acid, propionic acid, trichloroacetic acid, trif luoroacetic acid, etc.] and an inorganic acid [e. g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.]. The elimination using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].
The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature'is not critical and the reaction is usually carried out under cooling to warming.
The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.
Suitable reducing agents to be used in chemical reduction are a combination of metal [e. g. tin, zinc, iron, etc.] or metallic compound [e. g. chromium chloride;
chromium acetate, etc.] and an organic or inorganic acid [e. g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e. g.
platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e. g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, 25 palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts [e. g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e. g.
reduced cobalt, Raney cobalt, etc.], iron catalysts [e. g.
reduced iron, Raney iron, etc.), copper catalysts [e. g.
reduced copper, Raney copper, Ullman copper, etc.] and the like.
The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof.
Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.
The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
The reaction with an enzyme can be carried out by z,_ _ 2~~~'~~~~
reacting the compound [II] or a salt thereof with an enzyme suitable for the elimination reaction of N-acyl group.
Suitable example of said enzyme may include the one produced by certain microorganisms of the Actinoplanaceae, for example, Actinoplanes utahensis IFO-13244, Actinoplanes utahensis ATCC 12301, Actinoplanes missourienses NRRL 12053, ox the like; and the like.
This elimination reaction is usually carried out in a solvent such as phosphate buffer, Tris-FICl buffer or any other solvent which does not adversely influence the reaction The reaction temperature is not critical and the reaction can be carried out at room temperature or under warming.
Process 2 The object compound [Ib] or a salt thereof can be prepared by subjecting the compound [Ia] or a salt thereof to acylation reaction.
The a.cylation reaction of this process can be carried out by reacting the compound [Ia] or a salt thereof with aforesaid "acylating agent", for example, the compound [V]
or its reactive derivative at the carboxy group or a salt thereof .
.Suitable reactive derivative at the carboxy group of the compound [V] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examgles of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e. g.
dialkylphosphoric acid, phenylphosphoric acid diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, _ 22 -sulfonic acid [e. g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e. g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivaric acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.]; or aromatic carboxylic acid [e. g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole, tetrazole or 1-hydroxy-1H-benzotriazole; or an activated ester [e. g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH3)2~N=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e. g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound [V] to be used.
Suitable salts of the compound [V] and its reactive derivative can be referred to the ones as exemplified for the compound [I].
The reaction is usually carried out~in a conventional solvent such as water, alcohol [e. g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.
Tn this reaction, when the compound [V] is used in a 23 ~~4~ ~ ~i free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide;
N-cyclohexyl-N'-morgholinoethylcarbodiimide;
N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide;
N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide;
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, N,N'-carbonylbis-(2-methylimidazole);
pentamethyleneketene-N-cyclohexylimine;
diphenylketene-N-cyclohexylimine; ethoxyacetylene;
1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride;
thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.];
triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt;
2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroform~te, phosphorus oxychloride, methanesulfonyl chloride, etc.; or the like.
The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri(lower)alkylamine, pyridine, di(lower)alkylaminopyridine (e. g.
4-dimethylaminopyridine, etc.), N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.
The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
ur..~.o~~ z The object compound [Id] or a salt thereof can be prepared by subjecting a compound IIc] or a salt thereof to elimination reaction of amino protective group.
Suitable salts of the compounds [Ic] and [Id] can be referred to the ones as exemplified for the compound [I].
This elimination reaction can be carried out in accordance with a conventional method as explained above for Process 1.
Process 4 The object compound [If] or a salt thereof can be prepared by reacting a compound [Ie] or a salt thereof with a compound [III] or a salt thereof.
Suitable salt of the compound [If] can be referred to the ones as exemplified for the compound [I].
Suitable salt of the compound [III] can be referred to acid addition salts as exemplified for the compound [I].
The present reaction may be carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, methylene chloride, ethylene chloride, formamide, N,N-dimethylformamide, methanol, ethanol, diethyl ether, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the ~ compound [III] is in liquid, it can also be used as a solvent.
The reaction is. preferably conducted ir. the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, organic base such as trialkylamine, and the like.
The reaction temperature is not critical, and the reaction is usually carried out under cooling, at room temperature, under warming or under heating.

2~'~_ The present reaction is preferably carried out in the presence of alkali metal halide [e. g. sodium iodide, potassium iodide, etc.], alkali metal thiocyanate [e. g.
sodium thiocyanate, potassium thiocyanate, etc.] or the like.
Process 5 The object compound [Ig] or a salt thereof can be prepared by subjecting a compound [IV] or a salt thereof to acylation reaction.
Suitable salts of the compounds [Ig] and [IV] can be referred to the ones as exemplified for the compound [I].
Suitable "acylating agent" in this Process 5 may be an acid compound corresponding to the acyl group to be introduced, for example, phosphoric acid and its derivative (e. g. phosphoryl chloride, diphenylphosphorochloridate, etc.), sulfuric acid and its derivative [e. g. sulfur trioxide-pyridine, sulfur trioxide-tri(lower)alkylamine (e. g. trimethylamine, triethylamine, etc.), chlorosulfonic acid, etc.], or the like.
This reaction can be carried out in a conventional manner.
(to be continued to the next page) ...~a,~~: ~._.~~:.. ~:~~.~,_ .__~.,_..........._~.._ _.... y..._ .~

The process for preparing the starting compound [II]
or a salt thereof of the present invention is explained in detail in the following.
Process A_ The compound [II] or a salt thereof can be prepared by the fermentation process.
The fermentatian process is explained in detail in the following.
The compound [II] or a salt thereof of this invention can be produced by fermentation of the compound [IT] or a salt thereof-producing strain belonging to the genus Coleophoma such as Coleophoma sp. F-11899 in a nutrient .15 medium.
(i) Microorganism a Particulars of the microorganism used for producing the compound [II] or a salt thereof is explained in the following.
The strain F-11899 was originally isolated from a soil sample collected at Iwaki-shi, Fukushima-ken, Japan.
This organism grew rather restrictedly on various culture media, aad formed dark grey to brownish grey colonies.
Anamorph (conidiomata) produced on a steam-sterilized leaf segment affixed on a Miura's LCA platel) or a corn meal agar plate by inoculating the isolate, while neither teleomorph nor anamorph formed on the agar media. Its morphological, cultural and physiological characteristics axe as follows.
Cultural characteristics on various agar media are sumanarized in Table 1. Cultures on potato dextrose agar grew rather rapidly, attaining 3.5-4.0 cm in diameter - 27 _ after two weeks at 25°C. This colony surface was plane, felty, somewhat wrinkly and brownish grey. The colony center was pale grey to brownish grey, and covered with aerial hyphae. The reverse color was dark grey. Colonies on malt extract agar grew more restrictedly, attaining 2.5-3.0 cm in diameter under the same conditions. The surface was plane, thin to felty and olive brown. The colony center was yellowish grey, and covered with aerial hyphae. .The reverse was brownish grey.
The morphological characteristics were determined on basis of the cultures on a sterilized leaf affixed to a Miura's LCA plate. Conidiomata formed on the leaf segment alone. They were pycnidial, superficial, separate, discoid to ampulliform, flattened at the base, unilocular, thin-walled, black, 9.0-160(.-200) um in diameter and 40-70 " um high. ~Ostiole was.often single, circular, central, papillate, 10-30 unn in diameter and 10-20 Wn high.
Conidiophores formed from the lower layer of inner pycni.dial walls. They were hyaline, simple or sparingly branched, septate and smooth. Conidiogenous cells were enteroblastic, phialidic, determinate, ampulliform to obpyriform, hyaline, smooth, 5-8 x 4-6 dun, with a collarette. The collarettes were campanulate to cylindrical., and 14-18 x 3-5 um. Conidia were hyaline, cylindrical, thin-walled, aseptate, smooth and 14-16(-18) x 2-3 um.
' The vegetative hyphae were septate, brown, smooth and branched. The hyphal cells were cylindrical and 2-7 um thick. The chlamydospores were absent.
The strain F-11899 had a temperature range for growth of 0 to 31°C and an optimum temperature of 23 to 27°C on potato dextrose agar.
The above characteristics indicate that the strain F-11899 belongs to the order Coelomycetes2)~ 3), 4), Thus, we named the strain "Coelomycetes strain F-21899".

Table 1 Cultural characteristics of the strain F~-11899 Medium Cultural characteristics Malt extract agar G: Rather restrictedly, 2.5-3.0 cm (Blakeslee I915) S: Circular, plane, thin to felty, olive brown (4F5), arising aerial hyphae at the center (yellowish grey (4B2)) IO R: Brownish grey (4F2) Potato dextrose agar Gs Rather rapidly, 3.5-4.0 cm (Difco 0013) 8: Circular, plane, felty, somewhat wrinkly, brownish grey (4F2), I5 ~ arising aerial hyphae at the center (gale grey (4B1) to brownish grey (4F2)) R: Dark grey (4F1) 20 Czapeck's solution G: Very restrictedly, 1.0-1.5 cm agar (Raper~and Thorn S: Irregular, thin, scanty, 1943) immersed, subhyaline to white R: Subhyaline to white 25 g~o.~,aud dextrose G: Restrictedly, 2.0-2.5 cm agar (Difco 0109) S: Circular, plane, thin, white, sectoring, light brown (6D5) at the colony center R: Pale yellow (4A3) Oatmeal agar G: Fairly rapidly, 4.0-4.5 cm (Difco 0552) ~ S: Circular, plane, felty to cottony, dark grey (4FI) to brownish grey (4F2) R: Brownish grey (4D2) 2~'~~~~
Medium Cultural characteristics Emerson Yp Ss agar G: Restrictedly, 2.0-2.5 cm (Difco 0739) S: Circular to irregular, plane, felty, dark grey (4F1) tc~
brownish grey (4F2) R: Medium grey (4E1) to dark grey (4F1) Corn meal agar G: Rather restrictedly, 2.5-3.0 cm (Difco 0386) S: Circular, plane, thin to felty, dark grey (2FI) to olive (2F3.) R: Dark grey (2F1) to olive (2F3) MY20 agar G: Restrictedly, 1.5-2.0 cm S: Circular to irregular, thin, sectoring, yellowish white (4A2.) R: Pale yellow (4A3) to orange white (5A2) Abbreviations : G: growth, measuring colony size in diameter S: colony surface R: reverse These characteristics were observed after 14 days of incubation at 25°C. The color descriptions were based on the Methuen Handbmok of Colour5l.
1) ~~a~ g. ~d M. Y. Kudo: An a~~r-medium for aguatic Hyphomycetes.., Trans. Ycolo. Soc. Japan, ll:llfa-118, 197a.
2) Arx, J. A. von: The Genera of Fungi - Sporulating in Pure Culture (3rd ed.), 315 p., J. Cramer, Vaduz, 1974.

- .
3) Sutton. B. C.: The Coelomycetes - Fungi Imperfecti with Pycnidia, Acervuli and Stromata., 696 p., Commonwealth Mycological Institute, Kew, 1980.
4) Hawksworth, D. L., B. C. Sutton and G. C. Ainsworth:
Dictionary of the Fungi (7th ed.), 445 p., Commonwealth Mycological Institute, Kew., 1983.
5) Kornerup, A, and Wanscher, J. H.: Methuen Handbook of Colour (3rd ed.), 252 p., Methuen, London, 1983.
A culture of Coelomycetes strain F-11899 thus named has been deposited with the Fermentation Research Institute Agency of Industrial Science and Technology (1-3, Higashi 1 chome, Tsukuba-shi, IBARAKI 345 3APA1~T) on October 26, 1989 under the number of FERM BP-2635.
After that, however, we have further studied the classification of the strain F-11899, and have found that the strain F-11899 resembled Coleophoma empetri (Rostrup) Petrak 1929 2), 3), 4) belonging to the order Coelomycetes, but differed in some pycnidial characteristics : globose or flattened at the base, immersed, and not papillate.
Considering these characteristics, we classified this strain in more detail and renamed-it as "Coleophoma sp.
F-11899°' .
In this connection, we have already taken stag to amend the name, "Coelomycetes strain F-11899" to Coleophoma sp. F-11899 with the Fermentation Research Institute Agency of Industrial Science and Teahnolo~r on September 21, 1990.
(ii) Production of the compound [II] or a salt thereof The compound [II] or a salt thereof of this invention is produced when the compound [II] or a salt _ 31 _ ~~~~7~~3 thereof-producing strain belonging to the genus Cole ~homa is grown in a nutrient medium. containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.).
The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose or glycerin, or the like.
The preferred sources of nitrogen are yeast extract, peptone, gluten meal, cotton seed flour, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen coiapounds such as ammonium salts ( a . g. amanoniu~a nitrate, ammani.uza self ate, ammonium phosphate, etc.), urea or ama.no.acid, or the like.
The carbon. and nitrogen sources,. though advantageously employed in combination, need not to be used in their pure form because less pure materials,. which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable far use.
When desired, there maybe added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodiuia or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salt, or cobalt salts, or the like.
If necessary, especially when the culture medium foams seriously a defoaming agent, such as lipoid paraffin, fatty oil, plant oil, mineral oil or silicone, or the like may be added.
As in the case of the preferred methods used for the production of other biologically active. substances in massive amounts,. submerged aerobic cultural conditions are pref erred for the production of the co~apound [ II1 or a salt thereof in massive amouats.

For the production in small amounts, a shaking or surface culture in a flask ar bottle is employed.
Further, when the growth is carried out in large tanks, it is preferable to use the vegetative form of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production of the compound [II] or a salt thereof. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores or mycelia of the organism and culturing said inoculated medium, and then to transfer the cultured vegetative inoculum to large tanks. The medium, in which the vegetative inoculum is produced, is substantially the same as or different from the medium utilized for the production of the'compound [II) or a salt T
thereof . ~~
Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the ferinentor, by various pumping equipment or by the passage of sterile air thxough the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
The fermentation is usually conducted at a temperature between about 10°C and 40°C, preferably 20°C
to 30°C, for a period of about 50 hours to 150 hours, which may be varied according to fermentation conditions and scales.
When the fermentation is completed, the culture broth is then subjected for recovery of the compound [II] or a salt thereof to various procedures conventionally used for recovery and purification of biological active substances, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from as appropriate solvent or a mixture of some solvents, or the like.

2~~1.~'~~
According to this invention, in general, the compound [II] or a salt thereof is found both in the cultured mycelia and cultured broth. Accordingly, then the compound [II] or a salt thereof is removed from the whole broth by means of extraction using an appropriate organic solvent such as acetone or ethyl acetate, or a mixture of these solvents, or the like.
The extract is treated by a conventional manner to provide the compound [II] or a salt thereof, for example, the extract is concentrated by evaporation or distillation to a smaller amount and the resulting residue containing active material, i.e. the compound [II] or a salt thereof _ is purified by conventional purification procedures, for example, chromatography or recrystallization from an appropriate solvent or a mixture of some solvents.
When the object compound is isolated as a salt of the compound [II], it can be converted to the free compound [II] or another salt of the compound [II] according to a conventional manner.
Biological properties of the polypeptide compound [I] of the present invention In order to show the usefulness of the polypeptide compound [I] of the present invention, some biological data of the representative compounds are explained in. the following.
Test 1 Antimicrobial activity (1) .
Antimicrobial activity of the compound of Example 2 disclosed later (hereinafter referred to as FR131535 substance) was measured by micro-broth dilution method in 96 well multi-trays employing yeast nitrogen base dextrose medium. To a 50 ul sample solution with serial 2-fold dilution was added a SO ul of microorganism suspension in saline to yield a final concentration of 1 x 105 colony forming units/ml. The Candida cultures were incubated at 37°C for 22 hours. After incubation, the growth of microorganism in each well was determined by measuring the turbidity. The results were shown as IC50 value in which concentration the turbidity was half of that in the well without sample. The results are shown in Table 2.
Table 2 organism IC50 Candida albicans FP578 0.31 Candida tropicalis YC118 0.47 Test 2 Acute toxicity of FR131535 substance The acute toxicity of the FR131535 substance was determined to ICR mice (female, 4 weeks old) by a single intravenous injection. No toxic symptom was observed at the dose of 500 mg/kg.
Test 3 Antimicrobial activity (2) .
In vitro antimicrobial activity of the compound of Example 12 disclosed later (hereinafter referred to as FR139687 substance) was determined by the two-fold agar-plate dilution method as described below.
One loopful of an overnight culture of each test microorganism in Sabouraud broth containing 2 °s Glucose (105 viable cells per ml) was streaked on yeast nitrogen base dextrose agar (YNBDA) containing graded concentrations of the FR139687 substance, and the minimal inhibitory concentration (MIC) was expressed in terms of ug/ml after incubation at 30°C for 24 hours.
organism MIC (ug/ml) Candida albicans YU-1200 0.05 From the test results, it is realized that the polypeptide compound [I] of the present invention has an anti-microbial activity (especially, antifungal activity).
The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the polypeptide compound [I] or a 25 pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable fox use. And, if necessary, in addition, auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The polypeptide compound (I] or a pharmaceutical acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired antimicrobial effect upon the process or condition of diseases.
For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, pulmonary, or oral administration, or insufflation. While the dosage of therapeutically effective amount of the 2~~~'~t~~
polypeptide compound [I] varies from and also depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 20 mg of the polypeptide compound [I]
per kg weight of human being, in the case of intramuscular administration, a daily dose of 0.1 - 20 mg of the polypegtide compound [I] per kg weight of human being, in case of oral administration, a daily dose of 0.5 - 50 mg of the polypeptide compound [I] per kg weight of human being is generally given for treating or preventing infectious diseases.
The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.
(to be continued to the next page) ' Pre aration 1 To methanol (50 ml) was added thionyl chloride (8.73 ml) at -5°C and the mixture was stirred for 10 minutes and then D-2-(p-hydroxyphenyl)glycine (5 g) was added thereto under ice-cooling. The mixture was stirred for 12 hours at room temperature. The reaction mixture was evaporated under reduced pressure to give D-2-(p-hydroxyphenyl)-glycine methyl ester hydrochloride (6.3 g).
IR (Nujol.) . 3380, 1720, 1580, 1254 cm 1 NMR.(DMSO-d6, 8) . 3.70 (3H, s), 5.11 (1H, s), 6.83 (2H, d, J=8.6Hz), 7.28 (2H,. d, J=8.6Hz), 8 . 91 ( 2H, s) , 9 . 93 ( lFi, S) Preparation 2 To a solution of D-2-(p-hydroxgphenyl)glycine methyl ester hyd~oEhloride (6.3 g) and triethylamine (8.71 ml) in tetrahydrofuran (100 ml) was added di-t-hutyl dicarbonate (6.82 g). The mixture was stirred far 2 hours at room temperature. The reaction mixture-was added to diethyl ~ ether ~(1 ~.) and an insoluble material was filtered off, and th,e filtrate was evaporated under reduced.pressure to give N-(t-butoxycarbonyl)-D-2-(p-hydrnxyphenyl)glycine methyl ester (6.83 g).
IR iNujol) . 3420, 3354, 1724, 16fi4 cm 1 NMR (DMS4-d~, d) . 1.38 (9H, s), 3.5g (3H, s), 5.05 (1H, d, J=7..9Hz), 6.70 (2H, d, J=8.5Fiz), 7.16 (2I~, d, J=8.5Hz), 7.64 (1H, d, J=7.9Hz), 9.48 (1H, s) Preparation 3 To a suspension of N-(t-butoxycarbonyl)-~-2-(p-.hydroxyphenyl)glycine methyl ester (6.8 g) and potassium bicarbonate ( 1. 84 g ) in N , N-dimethylf orntami.de ( 3 4 m1 ) was added octyl bromide (4.176 ml). The mixture was stirred for 6 hears at 60°C. The reaction mixture was added.ta a - 38 °
mixture of water and ethyl.acetate. The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was (filtered off, and the ffiltrate was evaporated under reduced, pressure to give N-(t-butoxycarbonyl)-D-2-(p=octyloxyphenyl)glycine methyl ester (6.96 g).
IR (Nujol) . 1710, 1490, 1240, 1160 cm 1 NMR (DMSO-d6, 8) . 0.859 (3H, t, J=6.2Hz), 1.17-1.33 (lOH, m), 1.38 (9H, s), 1.60-1.80 (2H, ml, 3.59 (3H, s), 3.93 (2H, t, J=6.3Hz), 5.11 (1H, d, J=7.9Hz), 6.87 (2H, d, J=8.7Hz), 7.27 (2H, d, J=8.7Hz), 7.68 (1H, d, J=7.9Hz) Prevaration 4 To 4N aqueous solution of sodium hydroxide (8.77 ml) was added N-(t-butoxycarboayl)-D-2-(p-octyloxyphenyl)-glycine methyl ester (6.9 gl and stirred for 1.5 hours at room temperature. The reactioa mixture was.~added to a mixture of water and ethyl acetate and 1N hydrochloric acid was added thereto to adjust_the mixture to pH 3. The organic layer was separated and dried over magnesium sulf ate . The magnesium sulf ate was f filtered of f , and the filtrate was evaporated under reduced pressure to give N-(t-butoxycarbonyl)-D-2-(p-octyloxyphenyllglycine (3.9 gl~
NMR (DMSO-d6, d): 0.860 (3H, t, J=fi.BHz), 1.17 -1.33 (10H, m), 1.38 (9H, s), 1.60-1.80 (2H, m), 3.93 (2H, t, J=6.4Hz). 5.10 (lei, d, J=8.2Hz), 6.87 (2H, d, J=8.7Hz1. 7.28 (2H, d, J=8.7Hz), 7.46 (1H, d, J=8.2Hz) Prex~aration. 5 To a solution of N-(t-butoxycarhonyl)-D-2-(p-octyloxyphenyl)glycine (1 gl in acetonitrile (10 ml) and pyridine (0.213 ml) in acetanitrile (10 ml) was added N,N°-disuccinimidyl carbonate (0.675 g). The mixture was ~~~ ~~a~3 stirred for 12 hours at room temperature. The reaction mixture was added to a mixture of water and ethyl acetate.
The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give N-(t-butoxycarbonyl)-D-2-(p-octyloxyphenyl)glycine succinimido ester (0.92 g).
IR (Nujol) . 3350, 1810, 1730, 1680 cm-1 NMR (DMSQ-d6, 6) . 0.862 (3H, t, J=6.7Hz), 1.17-1.33 i0 (lOH, m), 1.40 (9H, s), 1.60-1.80 (2H, m), 2.77 . (4H, .s), 3.97 (2H, t, J=6.5Hz), 5.54 (1H, d, _ J=8.1HZ), 6.91 (2H, d, J=8.7Hz), 7.39 (2H, d, J=8.7Hz), 8.05 (1H, d, J=8.lHz) I5 Preparation.6 N-(t-Butoxycarbonyl)-L-tyrosine methyl ester was obtained according to a similar manner to that of Preparation 2.
IR (Nujol) . 3430, 3360, 1730, 1670, 1170 cm 1 20 NMR (DMSO-d6, d) . 1.33 (9H, s), 2.90 (2H, m), 3.59 (3H, s), 4.05 (1H, m), 6.65 (2H, d, J=8.4Hz), 7.00 (2H, d, J=8.4Hz), 7.21 (1H, d, J=8.OHz), 9.22 (1H, s) .
25 Pre ap ration 7 04-Octyl-N-it-butoxycarbonyl)-L-tyrosine methyl ester was obtained according to a similar manner to that of Preparation 3.
IR (Nujol) . 3350, 1735, 1685, 1250, 1170 cm 1 30 _ NMR (DMSO-d6, 8) . 0.859 (3H, t, J=6.7Hz), 1.20-1.30 (10H, m), 1.68 (2H, quintet, J=7.3Hz), 2.82 (2H, m), 3.60 (3H, s), 3.91 (2H, t, J=7.3Hz), 4.08 (LH, m), 6.81 (2H, d, J=8.6Hz), 7.12 (2H, d, J=8.6Hz), 7.25 (1H, d, J=8.OHz) Preparation 8 04-Octyl-N-(t-butoxycarbonyl)-L-tyrosine was ohtained according to a similar manner to that of Preparation 4.
IR (Nujol) . 3400-2900 (br), 1700, 1240, 1160 cm 1 NMR (DMSO-d6, 8) . 0.859 (3H, t, J=6.8Hz), 1.20-1.34 (lOH, m), 1.32 (9H, s), 1.fi8 (2H, quintet, J=7.OHz), 2.67-2.95 (1H, m), 3.90 (2H, t, J=7.OHz), 4.01 (1H, m), 6.81 (2H, d, J=8.6Hz), 7.02 (1H,. d, J=a.3Hz), 7.13 (2H, d, J=8.6Hz) v Preparation 9 04-Octyl-N-(t-butaxycarbonyl)-L-tyrosine succinimido ester was obtained according to a. similar manner to that of Preparation 5:
IR (Nujol) . 3350, 1780, 1720, 1690 cm 1 NMR (DMSO-d6, 8) . 0.864 (3H, t, J=6.?Hz), . 1.20-1.34 (lOH, m), 1.32 (9F~, s), 1.68 (ZH, quintet, J=7 .OHz) , 2. 8.2 ( 4Fi,, s) , 2. 80-3 . 24 ( 1H, m), 3.92 (2H, t, J=7.0Hz1. 4.44 (1H, m), 6.81 (2H, d, J=8.5Hz1, 7.22 (2H, d, J=8.5Hz), ?.60 (1H, d, J=8.3Hz) Preparation 10 (1) A seed medium (160 ml) consisting of sucrose 4%, cotton seed flour 2%, dried yeast 1%, peptone 1%, ~P04 0.2%, CaC03 0.2% and ~aesn 80* (made by I~AK.ARp,I CHE1~ICALS_ LTD.) 0.1% was poured into each of two 500 ml Erlenmeyer flasks and sterilized at 121°C for 34 minutes. A loapful of slant culture of Coleophnma sp. F-11x99 was inoculated to each of the medium and cultured under shaking condition at 25°C for 4 days.
A production medium (20 liters) consisti,ag of Pine Dex #3* (made by Matsutaai. Chemical Ltd.) 3%, glucose 1%, 3S wheat germ 1%, cotton seed flour 0.5%, RHZPO4 Z~S, Na2HP04~12820 * Trade-mark 1.5%, ZnS04~7H20 O.OOIO and Adekanol (defoaming agent, made by Asahi Denka Co., Ltd.) 0.050 was poured into a 30 liter-jar fermentor and sterilized at 121°C for 30 minutes.
The resultant seed culture broth (320 ml) was inoculated to the production medium and cultured at 25°C
for 4 days, agitated at 200 rpm and aerated at 20 liters per minute. To the cultured broth thus ohta,in.ed (20 liters) was added anwequal volume of acetone. After occasionally stirring at room temperature for a while, the broth was filtered. The filtrate was concentrated in vacuo to remove acetone. The aqueous filtrate (1f liters) was washed with two equal volume of ethyl acetate and extracted with n-butanol (10 liters) twice. The combined n-butanol layer was concentrated in vacuo and the residue was applied on a column (300 ml) of Silica gel 60 (made by E. Merck) and eluted with a stepwise organic solvent mixture consisting of dichloromethane-methanol. The fractions having anti-Candida activity were eluted in the range of the solvent mixture (3:1 through 1:1). The active fractions were combined and concentrated in vacuo to dryness. The residue was dissolved in SO~a aqueous methanol (15 ml) and applied an a column (250 ml) of ODS
*. _ YMC GEL (made by Yamamura Chemical Lab.). The column was washed with 50% ac;ueaus methanol and eluted with 800 agueous methanol. The eluate was concentrated and was further purified on a centrifugal partition chromatography (CPC) using a solvent system n-butanol:methaaal:water (4:1:5) of upper stationary phase and lower mobile phase in a descending mode. The pooled fractions containing the object compound (major component) were concentrated _ia vacuo and applied on a column (35 ml) of silica gel 60.
The column was developed with n-butanol:acetic acid~water.
(6:1:1). The active fractions were combined and concentrated in vacuo to dryness and dissolved in a small * Trade-mark 2a4~'~
volume of 50% aqueous methanol. The solution was passed through a column (3.5 ml) of ODS YMC GEL. The column was washed with 50% aqueous methanol and eluted with methanol.
The eluate was concentrated to dryness, dissolved in a small volume of water and adjusted to pH 7.0 with O.O1N
NaOH. The solution was freeze-dried to give a white powder of said compound in its sodium salt form (hereinafter referred to as FR901379 substance) (11 mg).
The FR901379 substance as obtained has the following physico-chemical properties.
Appearance white powder Nature neutral substance Melting point : . , 215-221°C (dec.) Specific rotation [a]D3 -20.3 (C: 0.5, X20) Molecular formula C51g81N8021SNa Elemental Analysis Calcd. . for C51HS1N8S021Na C 51.17, H 6.77, N 9.36, S 2.68 (%) Found . C 49.61, H 7.58, N 7.65, S 2.14 (%) Molecular weight HRFAB-MS : 1219.5078 (Calcd for C51H82N8S021 + 2Na - H: 1219.5032) ~~~~~~~~~b Solubility soluble : methanol, Mater slightly soluble : ethyl acetate, acetone insoluble : chloroform, n-hexane S
Color reaction positive : iodine vapor reaction, cerium sulfate reaction, ferric chloride reactioza, Ninhydrin reaction .
negative : Dragendorff reaction, Ehrlich reaction Thin layer chromatography (TLC) .
Stationary phase Developing solvent Rf value silica geld n-butanol:acetic acid;
water.(3:1:1) 0.36 ethyl acetate: isopropyl alcohol: water (5:3:1) 0.31 ~ Silica Gel 60 (made by E. Merck) Ultraviolet absorption spectrum ~methan:ol (E1% ) , 207(169), 276(13.5), 225(sh), max 1~ 283(sh) nm ~ ~methanol-~4. 0113-Na0I3 ( E1% ) . 209 ( 232 ) , 244( 59 . 5 ) , max 1~ 284(13.5), 294(sh) nm .Infrared absorption spectrum v~~ : 3350, 2920, 2840, 1660, 1625, 1530, 15101, 1435, 1270, 1240, 1070, 1045, 800, 755, 710 r°r-1 ~'"H Nuclear magnetic resonance spectrum ( CD3oD, 40 Ol~iz ) 8 . 7.30 (1H, d, J=2Hz), 7.03 (1H, dd, J=8 and 2HZ), 6.85 (1H, d, J=8Hz), 5.23 (1H, d, J=3~iZ), . -- 44 -5.06 (1H, d, J=4Hz), 4.93 (1H, d, J=3Hz), 4.59-4.51 (3H, m), 4.47-4.35 (5H, m), 4.29 (1H, dd, J=6 and 2Hz), 4.17 (1H, m), 4.07 (1H, m), 3.95-3.89 (2H, m), 3.76 (1H, broad d, J=llHz), 3.36 (1H, m), 2.75 (1H, dd, J=16 and 4Hz), 2.50 (1H, m), 2.47 (1H, dd, J=16 and 9Hz), 2.38 (1H, m), 2.21 (2H, m), 2.03-1.93 (3H, m), 1. 57 ~ ( 2H, ~m) , 1. 45-1. 20 ( 2~4H, m)., 1.19 ( 3H, d, J=6HZ), 1.08 (3H, d, J=6Hz), 0.90 (3H, t, J=7HZ) From the analysis of the above physical and chemical properties, and the result of the further investigation of identification of chemical structure, the chemical structure of the FR901379 substance has been identified and assigned as follows.
Ho ox $H
B3C NHOO(CH~)14CR3 .
H . o .0 FiN OR
0 ~ .
0 Cti3 . . . . ..
.RZN a H
HO
0 ~~f~ 0~

Na o-s--o a . , o $o Example 1 N-acyl group of FR901379 substance was eliminated by the reaction with an enzyme. In the following, this elimination process is explained in detail.
(1) Fermentation of Actinoplanes utahensis 2~~~'~~~~
The enzyme which is useful for eliminating N-acyl group of FR901379 substance is produced by certain microorganisms of the Actinoplanaceae, preferably the microorganism Actinoplanes utahensis IFO-13244.
A stock culture of Actinoplanes utahensis IFO-13244 is prepared and maintained on agar slant. A loopful of the slant culture was inoculated into a seed medium consisted of starch 1%, sucrose 1%, glucose 1%, cotton seed floux 1%, peptone 0.5%, soy bean meal 0.5% and CaC03 0.1%. The inoculated vegetative medium was incubated in a 225-ml wide mouth Erlenmeyer flask at 30°C for about 72 hours on a rotary shaker.
This incubated vegetative medium was used directly to inoculate into a production medium consisted of sucrose 2%, peanut powder 1%, K2HP04 0.12% KH2P04 Q-:05% and MgS04 7H20 0.025%. The inoculated production medium was allowed .
to ferment in a~~30-liter jar ferlnentor at a temperature of 30°C for about 80 hours. The fermentation medium was stirred with conventional agitators. at 250 rpm and aerated at 20 liters per minute. The vegetative mycelium was . . . . , . . .
collected from the fermented broth by filtration and once washed with water. The washed mycelium was directly used to eliminate N-aryl group of FR901379 substance as an enzyme source.
(2) Elimination Condition FR901379 substance was dissolved in 0.25 M phosphate buffer (pH 6.5) at a concentration~of 0.9 mg/ml. To a 36-liter of the solution was added a 2 kg~wet weight of washed.mycelium of Actinoplanes utahensis IFO-13244. The elimination reaction was carried out at 3?°C under for 23 hours. Reduction of FR901379 substance and increase of~
the deacylated FR901379 substance(hereinafter referred. to as FR1333.03 .substance) were measured using a HPLC.equipped - 4b with a reverse phase column. From a 30 g of FR901379 substance, a 22.2 g of FR133303 substance was formed in the reaction mixture.
(3) Isolation of FR133303 Substance The reaction mixture described above was filtered with a filter aid. .The mycelial.cake was discarded. The filtrate thus obtained was passed through a column of activated carbon (2 L). The column was washed with 6 L~of water and eluted with 12 L of 50°s aqueous acetone. The eluate was evaporated in vacuo to remove acetone and then passed through'a column (4 L) of YMC GEL ODS-AM 120-S50 (Yamamura Chemical Labs). The column was washed with water and eluted with 2% aqueous ~acetonitrile containing 50 mM NaFi2PO4. Elution was monitored by analytical FiPLC, using a column of LiChrosphe= 100 RP-18 (Cica-MERCK) and a solvent system of 3% aqueous acetonitrile containing 0.5°s ~'4R2p04 at a flow rate of 1 ml/min, detecting the FR133303 substance with a W monitor at 210 nm. The fractions containing the FR133303 substance were combined and passed through a column of activated carbon (400 ml).
The column was~washed with water and eluted with 50%-aqueous acetone. The eluate was concentrated in vacuo to remove acetone and lyophilized to give 16.4 g of ER133303 substance as a white powder.
FR133303 substance has following physico-chemical properties Appearance white powder Melting point 150-160°C ' (dec: ) * Trade-mark Specific rotation [o~]~'~ -31.17° (C: 1.0, H20) Molecular formula C35H5~.N8SC20Na Elemental Analysis Calcd : for C35H51N8S~20Na C 43.84, H 5.36, N 11.69, S 3.34 (%) Found : C 41.14, H 5.74, N 10.88, S 3.10 (%) solubility :
soluble . water slightly soluble : methanol insoluble . n-hexane Color reaction positive : i~dine vapor reaction, cerium sulfate reaction, Ninhydrin reaction negative : Molish reaction Thin layer chromatography (TLC) .
Stationary phase Developing solvent Rf value silica gel* n-butanol:acetic acid water (3:.1:2) 0.15 * Silica Gel 60 (made by E. Merck) Ultraviolet absorption spectrum Amax (E~%~) . 201(340), 273(18), 224(sh), 281(sh) nm - 4g _ r H20+0.O1N-NaOH

~'max (Ei~Cm) . 207(414), 243(122), 292 (34) Infrared absorption spectrum v~~ : 3350, 2920, 1660, 1625, 1515, 1440, 1270, 1080, 1045, 800, 755, 715 cm 1 1H Nuclear magnetic resonance spectrum (D20, 400MHz) d . 7.31 (1H, d, J=2Hz), 7.12 (1F3, dd, J=2Hz and 8Hz), 7. f6 (1H, d, J=8Hz), 5.40 (1H, d, J=3Hz), 5.04 (1H, d, J=3.5Hz), 4.94 (1H, d, J=6Hz), 4.73-4.55 (3H, m), 4.51-4.38 (4H, m), 4.31-4.23 (3H, m), 4.11-4.06 (2H, m), 3.94-3.89 (2H, m), 3.41 (1H, m), 2.60=2.34 (5H, m), 2.14 (1H, m), 2.03 (1H, m), 1~.28.(3H, d, J=6Hz),.1:01 (3H, d, J=6.5Hz) ~'3~ Nuclear magnetic resonance spectrum (D20, 100i~z) d . 178.3 (s), 175.9 (s), 174.3 (s), 174.2 (s), 174.0 (s), 171.8 (s), 171.3 (s), 150.9 (s), 141.5 (s), 134.4 (s), 128.2 (d), 124.5 (d), 120.3 (d), 78.1 (d), 77.0 (d), 76.9 (d), 76.6 (d), 72.9 (d), 72.8 (d), 71.2 (d), 69.3 (d), 69.2 (d), 63.7 (d), 60.1 (d), 58.3 (t), 58.0 (d), 56.9 (d), 55.3 (d), 54.7 (t), 41.8 (t), 39.7 (d), 39.5 (t), 33.5 (t), 21.4 (q), 13.3 (q) The chemical structure of ER133303 substance has been identified and assigned as follows.

2~~'~~
HO OH

NH

N o HN off ~ ~~3 N
~~" OH

IO ~ .N
Example 2 (1) A solution of 4-hydroxybenzoic acid (19.2 g) in 10%
NaOH (120 ml) was dropwise added to 480 ml of dimethyl sulfoxide over 30 minutes during which the.temparature in .
reaction mixture was controlled between 30 and 40°C.
After adding, the solution was cooled to 17-20°C.
~ 1-Hromooctane (28.95 g) was dropwise added to the solution over 30 minutes and the reaction mixture was vigorously stirred for 4 hours at roam temperature. The reaction mixture was poured into ice water (1200 ml) and acidified' ' with 40 ml of conc. hydrochloric acid. After vigorously, stirring for another 1 hour, the,.resulting solid was, , ,.
removed by filtration and dissolved in 60 ml of acetonitrile. The solution was refluxed over 30 minutes and was allowed to stand overnight at room temperature to yield 4-octyloxybenzoic acid (13.8 g) as a crystal (MP
96°C, Anal Caldd. for C15H2203 ' C 71.97, Fi 8.86, E'ound : G 71.30, H 8:89). .
To a solution of 4-octyloxybenzoic acid (13.8 g) in diethyl ether (552 ml) were added 2,4,5-trichlorophenol (10.87 g) and N,N°-dicyclohexylcarbodiimide (11.37 g).
The solution, was stirred under a nitrogen atmosphere for ~'max (Ei~Cm) . 207(414), 243(122), 18 hours at room temperature. The precipitate was removed by filtration and the ffiltrate was concentrated in, vacuo.
The residue was dissolved in petroleum ether and Was allowed to stand on ice-water. The resulting crystals (15.2 g) were filtered and dissalued in warm n-hexane (150 ml). After standing overnight at room temperature, the resulting crystal was removed by filtration. The filtrate was concentrated to an oil which was purified by a column chromatography over silica gel using a mixture of ethyl acetate and n-hexane to give 2,4,5-trichlorophenyl 4-octyloxybenzoate (7.58 g)(I~ 53°C, Anal Calcd. for C21H2303C13 ~ C1 24.75, Found . C1 24.05).
(2) To a solution of FR133303 substance (2.04 g) in N,N-dimethylformamide (60 ml) were added 2,4,5-trichlorophenyl 4-dctyloxybenzoate (2.04 g)~ and 4-dimethylaminopyridine (0.283 g). The solution was stirred under a nitrogen atmosphere at room temperature for 15 hours.. 4-Dimethylaminopyridine (0.20 g) was added to the solution and mixture was stirred for another 24 hours. The reaction mixture was pcured into water (600 ml) and the pFi was adjusted to 6.Q. The mixture was washed twice with an equal volume of ethyl acetate and concentrated to 30 ml. The concentrate was applied on a column (150 ml) of DEAF-Toyopearl (Cl type, manufactured by Tosoh). The column Was washed with 50% agueous .~ methanol and developed with 50% agueous methanol containing 1M sodium chloride ~ac,~ueous. solution. The elution of product was assessed bg the same FiPLC systeFa as ~30 described in Example 1(.3) except that the concentration of acetonitrile in solvent was 40%. -The fractions containing the object compound were pooled and evaporated in vacuo to remove methanol. The solution was absorbed on a column (1 L) of YMC GEL ODS-AM 120-S50 in order to remo~re salt. The column was washed with water and eluted with 30% aqueous * Trade-mark acetonitrile. The eluate was evaporated in va~cuo to remove acetonitrile and lyophylized to give the object compound (hereinafter referred to as FR131535 substance) (1.4 g) as a white powder.
FR131535 substance has following physico°chemical properties :
Appearance white powder Melting point :
170-189°C (dec.) , Specific rotation :
[c]DO' -14.4° (C: 10, H2o) Molecular formula . C50H71N8S022Na 20' Elemental Analysis :
Calcd : for C50H71N8S022Na~6H20 C 46.22, H 6.44, N 8.62, S 2.46, Na 1.77 (%) Found : C 46.80, H 6.13; N 8.78, S 1.96, Na 1.81 (%) Solubility soluble . methanol, water slightly soluble : acetone insoluble . n-hexane Color reaction :
positive : iodine vapor reaction, cerium sulfate reaction ~~~~~t3 Thin layer chromatography (TLC) Stationary phase Developing solvent Rf value silica gel* n-butanol:acetic acid:
water (6:1:1) 0.21 * Silica Gel 60 (made by E. Merck}
Tnfrared absorption spectrum v~~ : 3330, 2900, 2850, 1620, 1500, 1430, 1270, 1250, 1170, 1110, 1080, 1040, 960, 940, 880, 840, 800, 750, 710 cm 1 1H Nuclear magnetic resonance spectrum (CD3oD, 2~Ol~iZ) ' - .
3 . 7.78 (2H, d, J-8Hz),'7.31 (7.H, d, J-2Hz), 7.03 . (1H~, dd, J=2Hz and 8Hz), 6..96 (2H, d, J=8Hz), 6.87 (1H, d, J=$Hz), 5.33 (~H, d, J=3Hz), 5.08 (1H, d, J=4Hz), 4.99 (1H, d, J=3Hz), 4.80-3.20 . (17H, m), 2.83 (1H,'m), 2.65-2.30 (4H, m),~
2.22_-1.90 (2H, m), 1.79 (2H, m), 1.56-1.25 (lOH, m), 1.19 (3H, d, J=6Hz), 1.06 (3H, d, J=6.5Hz);
0.90 (3H, t, J=6.5Hz) The chemical structure of FR131535 substance has been identified and assigned as follows.
Ho, off go 0 g3C g N 7 ~ O(CH2)7CH3 O HQ ~o H ~ OH
~3 HO ~ ~~ OH
0 ~
3 5 Nao-S-0 Ho In the following, the structures of the compounds of Examples 3 to 11 are shown.
HO OH
Ii0 0 N
0 H . HN OH
g N ~ . 0 ~~3 .
2 HO 0 ~~ ~~. OH
n ~OH 0 Na0-S-0 ~
11 .
. ~ g0 Example Compound No. R
No.

(D) .
H ~ ~ O(CH2)7CH3 -CO

3 FR138260 , i NHCOOtBu (D) ~ ~

4 ~ FR138727 O(CH2)7CH3 -COCH

~2 5 FR138364 C ~~2 / \ O(Cx2)7CH3 .

NACOOtHu ..
6 FR138261 -COOtBu 8 FR138728 -COCH2Br 9 FR138538 -COO ~

-COC N

CH30-N S NH2.
10 ~ ~
Example 3 To a solution of FR133303 substance (1 g) and N-(t-butnxycarbonyl)-D-2-(p-octyloxyphenyl)glycine succinimido ester (0.596 g) in N,N-dimethylformamide (3 mh) was added 4-dimethylaminopyridine (0.165g). The mixture was stirred for l2 hours at room temperature. The reaction mixture was added to water (30 ml) and then adjusted to pH 6. The aqueous solution was washed with ethyl acetate, and subjected to ion exchange chromatography on DEAF-Toyopearl (C~.~ )(60 ml) and eluted with 50% methanol in 1M aqueous solution of sodium chloride. The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol. The aqueous solution was adjusted to pH
4.5 with 1N hydrochloric acid and subjected to column chromatography on Diction FOP-20 (Trademark, Manufactured by Mitsubishi Chemical Industries) (130 ml) and eluted with 80% aqueous methanol. The fractions containi~y the object compound were combined and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give object acylated compo~ind (hereinafter referred to as FR138260 substance) (0.77 g).

2~~'~~
IR (Nuaol) . 3300, 1660, 1500, 1240, 1045, 800, 720 cm 1 NMR (CD30D, 8) . 0.92 (3H, t, J=6.SHz}, 1.05 (3H, d, J=6.8Hz), 1.I7-1.33 (13H, m), 1.43 (9H, s), 1.6-1.8 (2H, m}, 1.9-2.1 (3H, m), 2.50 (3H, m), 2.75 (1H, dd, J=l6Hz and 4Hz), 3.35 (1H, m), 3.?-3.8 (1H, m), 3.93 (2H, t, J=6.2Hz), ~.9-4.2 (5H, m), 4.3-4.5 (5H, m}, 4.5-4.7 (3H, m), 4.97 (1H, d, J=3Hz), 5.05 (1H, d, J=4Hz), 5.11 (1H, s), 5.30 (1H, d, 3=3Hz), 6.85 (1H, d, J=8.3Hz), 6.86 (2H, d, J=8.6Hz), 7.02 (1H, d, J=8.3Hz), 7.26 (2H, d, J=8.6Hz), 7.31 (1H, s) FAB-MS : e/z = 1343 (M + Na) 25 Example 4 FR138260 substance obtained in Example 3 ,(0.25 g) was added to trifluoroacetic acid (1.25 ml} and stirred for 10 minutes. The reaction mixture was added to water (30 ml) and then adjusted to pH 4.5 with saturated aqueous solution of sodium bicarbonate. The aqueous solution was subjected to column chromatography on Diaion HP-20 (100 ml) and eluted with 80~ aqueous methanol. The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give the object compound (hereinafter referred to as FR138?27 substance) (15 mg).
NMR (cD30D, 8) . 0.90 (3H, t, J=6.8Hz), 1.05 (3H, d, J=6.8Hz), 1.17-1.33 (13H, m), I.6-1.8 (2H, m), 1.9-2.1 (3H, m), 2.50 (1H, m), 2.75 (1H, dd, J=l6Hz and 4Hz), 3.40 (lli, m), 3.7-3.8 (1H, m), 3.98 (2H, t, J=6.2Hz}, 3.9-4.2 (5H, m}, 4.3-4.5 (5H, m), 4.5-4.7 (3H, m), 4.97 (1H, d, J=3Hz}, 5.06 (1H, s), 5.20 (lFi, d, J=3Hz), 5.40 (1H, d, J=3Hz), 6.85 (1H, d, J=8.3Hz), 6.95 (2H, d, J=8.5Hz), 7.02 (1H, d, J=8.3Hz}, 7.30 (1H, d, J=8.5Hz), 7.44 (1H, s) FRB-MS : e/z = 1259 (M + K) ~~~~t~~t~a.~
Example 5 ER138364 substance was obtained by reacting FR133303 substance with 04-octyl-13-(t-butoxycarbonyl)-L-tyrosine succinimido ester according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1660, 1620, 1240, 1050 cm 1 NMR (CD30D, ~.) . 0.904 (3H, t, J=6.8Hz), 1.06 (3H, d, 3=6.8Hz), 1.17 (3H, d, J=6.7Hz), 1.20-1.30 (IOH,.m), 1.35 (9H, s), 1.74 (2H, quintet, J=6.5Hx), 1.9-2.1 (3H, m), 2.45 (3H, m), 2.76 (1H, dd, J=l6Hz ana 4Hz), 3.0-3.1 (2H, m), 3.37 (1H, m), 3.77 (1H, d, J=113Jz), 3.92 (2H, t, J=6.8Hz), 3.9-4.2 (7H, m), 4.3-4.5 tSH, m), 4 . S-4. 6 ( 3Fi, m) , 4. 94 ( 1H, d, J=3Hz~ , 5 . 0.5 ( 1H, d,~J=3.8Hz), 5.31 (lFi, d, 3=3Hz), 6.79 (2H, d, J=8.SFiz), 6.85.(1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2Hz), 7.12 (2Hr d. J=8.5Hz), 7.31 (1H, d, J=2Hz) EAB-MS : e/z = 1357 (M, + Na) Example 6 A solution of FR133303 substance (0.5 g) in a mixture of water (5 ml) and tetrahydrofuraa (5 ml) was adjusted to pH 7 with saturated aqueous solution of sodium bicarbonate.
and N,N-di-t-butglcarbonate (0.114 g) was added thereto at room temperature. The mixture was stirred fvr 5 hours at room' temperature maintaining gH 7 with saturated aguedus solution of sodium bicarbonate. The reaction mixture was added to water and adjusted to pH6. The agueous solution was washed with ethyl acetate, and subjected to ion exchange chromatographg on DEAE-Tnyogearl (C~. ) (30 ml) and eluted with 50~ methanol in 1M agueous solution of sodium chloride. The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol. The aqueous solution was adjusted to pH 4.5 with 1N hydrochloric acid and subjected to column chromatography on Diaion HP-20 (100 ml) and eluted with 80% aqueous methanol. The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol.
The residue was lyophilized to give the object acylated IO compound (hereinafter referred to as FR138261 substance) (0.145 g).
IR (Nujol) . 3300, 1660, 1620, 1240, 1050 cm 1 NMR (CD30D, d) . 1.06 (3H,. d, J=6.8Hz), 1.18 (3H, d, J=6.0Hz), 1.40 {9H, s), 1.9-2.1 (3H, m), 2.44 ' (3H, m), 2.82 (lFi, dd, J=l6Hz and 4Hz), 3.37 (1H, m), 3F.75 (7.H, d, J=llHz), 3.89-4 (2H, m), 4.10 {lH,.m), 4.15 (1H, m); 4.29 {1H, dd, J=6HZ
and 2Hz), 4.36-4.45 (5H, m); 4.5-4.6 (3H, m), 4.97 (lFi, d, J=3Hz), 5.06 (1H; dd, J=8.2Hz and 4Hz), 5.33 (1H, d, J=3Hz), 6.85 (lIi, d, J=8.3HZ), 7.03 (1H, dd, J=8.3HZ and 2Hz), 7.30 {1H, d, J=2Hz), 7.50 (1H, d, J=8.2Hz) FAB-MS : e/z = 1081 (M + Na) Example 7 FR138363 substance was obtained by reacting FR133303 substance with acetyl chloride according to a similar manner to that of Example 6.
IR (Nujol) . 3300, 1620, 1250, 1040 czn 1 Nl~t {CD30D, a) . 1.06 (3H, d, J=6.8Hz), 1.20 (3H, d, J=6Hz), 1.78-2.05 (3H, m), 1.96 (3H, s), 2.21-2.54 (3H, m), 2.95 (1H, m), 3.35-3.42 (1H, m), 3.58-4.42 (llFi, m), 4.50-5.05 (5H, m), 5.23 (1H, m), 6.88 {lFi, d, J=8.3Hz), 7.05 (1H, dd, J=8.3Hz and 2Hz), 7.35 {1H, d, J=2Hz) 5g FAB-MS : 1023 (M + Na) Example 8 FR138728 substance was obtained by reacting FR133303 substance ~rith 2-bromoacetyl chloride according to a similar manner to that of Exam' lp a 6.
IR (Nujol) . 3300, 1660, 1620, 1500, 1220, 1040 cm 1 NMR (CD3oD, d) . 1.06 (3H, d, J=6.9Hz), 1.I7 (3H, d, J=6.lHz), 1.9-2.1 (3H, m), 2.50 (.3H, m), 2.80 (1H, dd, J=l6Hz and 4Hz), 3.37 (1H, m), 3.6-4.0 (5H, m), 4.09 (1H, m), 4.16 (1H, m), 4.29 (1H, dd, J=6Hz and 2Hz), 4.36-4.45 (5H, m), 4.5-4.7 (3H, m), 4.97 (1FI, d, J=3Hz), 5.04 (1H, dd, J=8.6Hz and 4Hz), 5.25 (1H, d, J=3.lHz), 6.85 (1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2.lHz), ?.31 (lFi, d, J=2Hz), 7.52 (1H, d, J=8.6Hz) _.
FAB-MS : e/z = 1203.(M + Na) Ex~le 9 FR138538 substance was obtained by reacting FR133303 substance with benzoyl chloride according to a similar manner to that of Example 6.
TR (Nujol) . 3300, 1640, 1240 cm 1 NMR (C;D30D, d) . 1.05 (3H, d, J=6.8Hz), 1.18 (3H, d, J=6Hz), 1.89-2.12 (3H, m), 2.31-2.53 (3H, m), 2.75 (1H, dd, J=12HZ and 4Hz), 3.38 (1H, m), 3.76 (1H, d, J=llHz), 3.87-3.98 (1H, m), 4.02-4.18 (2H, m), 4.22-4.32 (4H, m), 4.37-4.40 (3H, m), 4.49-4.62 (3H, m), 4.98 (1H, m), 5.02 (1H, m), 5.37 (lA, d, J=3Hz), 6~85 (1H, d, J=8.3Hz), 7.04 (1H, dd, J=B..sHz arid 2H2), 7.11-7.50 (6H, m) FAB-MS : e/z = 1101 (M + Na) 2~~'~E
Example 10 FR138539 substance was obtained by reacting FR133303 substance with 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid according to a similar manner to S. that of Example 6.
IR (Nujol) . 3300, 1650, 1620, 1520, 1260, 1040 cm-1 NMR (CD30D, 8) . 1.OS (3H, d, J=6.SHz), 1.21 (3H, d, J=5.9Hz), 1.89-2.21 (3H, m), 2.29-2.61 (3H, m), 2.78-2.89 (1H, m), 3.32-3.42 (1H, m), 3.76-3.82 (1H, m), 3.91-4.01 (2H, m), 3.95 (3H, s), 4.13 ' (1H, m), 4.16 (1H, m), 4.24-4.27 (1H, m), 4.32-4.43 (5H, m),.4.46-4.62 (3H, m), 4.97-4.99 (1H, m), 5.08 (1H, m), 5.41 (1H, m), 6.79 (1H, s), 6.86'(1H, d, J=8.lHz), 7.04'(1H, dd, J=8.lHz and 2Hz), 7.31 (1H, d, J=2Hz), 7.51 (1H, d, J=7Hz) FAB-MS : e/z -'1143 (M~) Example 11 ~R138365 substance was obtained by reacting FR133303 substance with tosyl chloride according to a similar manner to that of Example 6.
IR (Nujol) . 3300, 1650, 1620, 1260, 1060 cm 1 NMR (CD30D, d) . 0.75 (3H, d, J=6.8Hz), 1.07 (3H, d, J=6.OHz), 1.61-1.79 (IH, m), 1.91-2.05 (3H, m), 2.30-2.59 (3H, m), 3.36 (1H, m), 3.68 (1H, d, J=llHz), 3.81-4.07 (4H, m), 4.22 (1H, m), 4.32-4.40 (5H, m), 4.42-4.60 (3H, m), 4.7 (1H, m), 5.0 (lA, m), 5.42 (1H, d, J=3Hz), 6.85 (1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2Hz), 7.29-?.33 (3H, m), 7.75 (1H, d, J=8.3Hz) FAB°MS : e/z = 1135 (M + Na) Preparation 11 _ To a solution of 6-hydroxy-2-naphthoic acid (1 g) in the mixture of 10 $ sodium hydroxide aqueous solution (4.25 ml) and dimethylsulfoxide (17 ml) was added octyl bromide (0.918 ml). The mixture was stirred for 6 hours at 60 °C.
The reaction mixture was added to a mixture of water and ethyl acetate and adjusted to pH 3 with cone.
hydrochloric acid. The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 6-octyloxy-2-naphthoic acid (0.91 g).
IR (Nujol) . 1670, 1620, 1210 cm 1 NMR (DMSO-d6,8) . 0.86 (3H, t, J=6.7 Hz), 1.2 - 1.6 (lOH, m), 1.78 (2H, m), 4.10 (2H, t, J=6.7 Hz), 7.19 (1H, dd, J=2.3 and 8.8 Hz), 7.36 (1H, d, J=2.3 Hz), 7.83 (1H, d, J=8.8 Hz), 7.97 (2H, d, J=8.8 Hz), 8.52 (1H, s) Preparation 12 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.703 g) was added to a solution of 6-octyloxy-2-naphthoic acid (0.85 g) and 1-hydroxy-1H-benzotriazole (0.382 g) in ethyl acetate (26 ml). The mixture was stirred for two hours at room temperature.
The reaction mixture was added to water and the separated organic layer was washed with water and sodium chloride aqueous solution. Then the organic layer was dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 1-(6-octyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide (0.74 g).

IR (Nujol) . 1770, 1740, 1620, 1190, 1020, 740 cm 1 NMR (CDC13, d) . 0.90 (3H, t, J=6.8 Hz), 1.2 - 1.6 (IOH, m), 1.89 (2H, m), 4.14 (2H, t, J=6.8 Hz), 7.1 - 7.3 (2H, m), 7.4 - 7.6 (3H, m), 7.8 - 8.0 (2H, m), 8.1 - 8.2 (2H, m), 8.80 (1H, s) In the following, the structure of the compound of Example 12 is shown.
l30 off NH

HN OH

H H 0 ~~3 AO ~~~~' OH
~OH 0 Na0- i-0 ~
0 ___ Example No. Compound No. R
O(CH2)7CH3 (to be continued to the next page) ~ 62 -Example 12 To a solution of FR133303 substance (0.5 g) and 1-(6-octyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide (0.271 . g) in N,N-dimethylformamide (1.5 ml) was added 4-dimethy7.aminopyridine (0.0828 g). The mixture was stirred for 12 hours at room temperature.
The reaction mixture was added to water and adjusted to pH 6. The aqueous solution was washed with ethyl acetate, and subjected to ion exchange chromatography on DEAF-Toyopearl (C1 ) (30 ml) and eluted with 50 ~ methanol in 1M sodium chloride solution . The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol. The aqueous solution was adjusted to pH 4.5 with 1N hydrochloric acid and subjected to column chromatography on Diaion HP-20 (65 ml) and eluted with 80 ~ aqueous methanol. The fractions containing the object compound were combined and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give object acylated compound (hereinafter referred to as FR139687 substance) (0.214 g).
IR (Nujol) . 3300, 1620, 1500 cm 1 NMR (DMSO-d6 + D20, d) . 0.86 (3H, t, J=6.8 Hz), 0.97 (3H, d, J=6.8 Hz), 1.06 (3H, d, J=6.8 Hz), 1.2 -1.5 (lOH, m), 1.6 - 2.0 (5H, m), 2.? - 2.5 (3H, m), 2.4 - 2.6 (1H, m), 3.18 (1H, m), 3.6 - 3.9 1H, m), 4.0 - 4.6 (15H, m), 4.84 (1H, d, J=3 Hz), 4.90 (1H, d, J=3 Hz), 5.11 (1H, d, J=3 Hz), 6.76 (1H, d, J=8.3 Hz), 6.93 (1H, d, J=8.3 Hz), 7.13 (1H, s), 7.25 (1H, d, J=8.3 Hz), 7.39 (1H, s), 7.8 - 8.0 (3H, m), 8.44 (1H, s) FAB-MS e/z=1264 (M+Na) '.~he following compounds (Preparations 13 to 16) were obtained according to a similar manner to that of Preparation 5.
Preparation 13 N-(t-Butoxycarbonyl)-L-2-(2-naphthyl)glycine succinimido ester IR (NUjol) . 3350, 1800, 1770, 1730, 1680, 1500, 1200 cm Preparation 14 Succinimido 2-(4-biphenylyl)acetate IR (Nujol) . 1800, 177p, 1720, 1200 cm 1 NMR (DMSO-d6, d) . 2.82 (4H, s), 4.17 (2H, s), 7.30-7.50 (5H, m), 7.45 (2H, d, J=8.lHz), 7.67 (2H, d, J=8.lHz) Preparation 15 Succinimido 4-t-butylbenzoate IR (Nujol) . 1760, 1730, 1200, 1070, 990 Cm-1 NMR (DMSO-d6, 8) . 1.33 (9H, s), 2.89 (4H, s), 7.68 (2H, d, J=8.5Hz), 8.03 (2H, d, ,~=8.5Hz) Preparation 16 Succinimido 4-(4-phenylbutoxy)benzoate IR (Nujol) . 1730, 1600, 1240, 1170, 1070 cm 1 NMR (DMSO-d6, d) . 1.75 (4H, m), 2.65 (2H, m), 4.14 (2H, m), 7.15 (2H, d, J=8.9Hz), 7.13-7.35 (5H, m), 8.03 (2H, d, J=8.9Hz) Preparation 17 To neat 3,7-dimethyloctanol (5 ml) was added.
phosphorus tribromide (1.01 ml). The mixture was stirred for 4 hours at 60°C. The reaction mixture was added to a mixture of water and n-hexane. The organic layer was 2Q~~~t.~~
separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 3,7-dimethyloctyl bromide (4.40 g).
IR (Neat) . 2900, 1450 cm 1 NMR (CDC13, d) . 0.87 (6H, d, J=6.6Hz), 0.89 (3H, d, J=6.4Hz), 1.1-1.3 (6H, m), l.5-1.9 (4H, m), 3.3-3.5 (2H, m) The following compounds (Preparations 18 to 23) were obtained according to a similar manner to that of Preparation 11.
Preparation 18 4-[4-(Octyloxy)phenoxy]benzoic acid IR (Nujol) . 1680, 1600, 1240, 840 cm 1 NMR (DMSO-d6, 8) . 0.87 (3H, t, J=6.7Hz), 1.1-1.6 (lOH, m), 1.71 (2H, m), 3.96 (2H, t, J=6.4Hz), 6.9-7.1 (6H, m), 7.92 (2H, d, J=8.7Hz), 12.8 (1H, br s) Preparation 19 6-(Butoxy)-2-naphthoic acid IR ENujol) . 1660, 1610, 1205 cm 1 NMR (DMSO-d6, 8) . 0.96 (3H, t, J=7.29Hz), 1.48 (2H, qt, J=7.29Hz and 7Hz), 1.78 (2H, tt, J=7Hz and 6.45Hz), 4.12 (2H, t, J=6.45Hz), 7.24 (1H, dd, J=9.OHz and 2.3Hz), 7.40 (1H, d, J=2.3Hz), 7.86 (1H, d, J=8.7Hz), 7.94 (1H, d, J=8.7Hz), 8.01 (1H, d, J=9.OHz), 8.52 (1H, s) Preparation 20 6-Decyloxy-2-naphthoic acid IR (Nujol) . 1670, 1620, 1210 cm 1 NMR (DMSO-d6, d) . 0.85 (3H, t, J=6.7Hz), .,...-..-._. ~...~.-..~..-t..,..a-..~ _~..,-~ .~~~R.... . . ... . ,.,,.-,~...~.,~..,.4.,..

1. 2-1. 6 (14H, m) , 1.78 ( 2H, m) , 4.11 ( 2H, t, J=6.4Hz), 7.23 (1H, dd, J=8.9Hz arid 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.86 (1H, d,.J=8.7Hz), 7.93 (1H, d, J=8.7Hz1. 8.01 (1H, d, J=8.9Hz), 8.5 (1H, s) Preparation 21 6-Hexyloxy-2-naphthoic acid IR (Nujol) . 1660, 1620, 1290, 1210 cm NMR (DMSO-d6, d) . 0.89 (3H, t, J=6.8Hz), 1.2-1.6 (6H, m), 1.78 (2H, quint, J=6.5Hz), 4.11 (2H, t, J=6.5Hz), 7.23 (1H, dd, J=9.OHz and 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.86 (1H, d, J=8.7Hz), 7.94 (1H, d, J=8.7Hz), 8.01 (1H, d, J=9.OHz), 8.52 25 (1H, s) Preparation 22 6-Dodecyloxy-2-naphthoic acid IR (Nujol) . 1670, 1620, 1210 cm 1 NMR (DMSO-d6, 8) . 0.85 (3H, t, J=6.7Hz), 1.20-1.60 (18H, m), 1.78 (2H, m), 4.11 (2H, t, J=6.5Hz), 7.22 (1H, dd, J=9.OHz and 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.85 (1H, d, J=8.7Hz), 7.93 (1H, d, J=8.7Hz), 8.00 (1H, d, J=9.OHz), 8.51 (1H, s), 12.90 (1H, s) Preparation 23 6-(3,7-Dimethyloctyloxy)-2-naphthoic acid IR (Nujol) . 1660, 1610, 1290, 1210 cm 1 NMR (DMSO-d6, 8) . 0.84 (6H, d, J=6.6Hz), 0.94 (3H, d, J=6.lHz), 1.1-1.4 (6H, m), 1.4-1.9 (4H, m), 4.15 (2H, t, J=6.7Hz), 7.22 (1H, dd, J=9.OHz and 2.4Hz), 7.41 (1H, d, J=2.4Hz), 7.86 (1H, d, J=8.6Hz), 7.93 (1H, d, J=8.6Hz), 8.01 (1H, d, J=9.OHz), 8.52 (1H, s) 2~~~°~~.
The following compounds (Preparations 24 to 31) were obtained according to a similar manner to that of Preparation 12.
Preparation 24 1-(4-(4-Octyloxy)phenoxy]benzoyl-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1730, 1600, 1500, 1230, 980 cm-1 Preparation 25 1-(6-Butoxy-2-naphthoyl)-1H-benzotriazole-3-oxide IR (Nujol) . 1760, 1610, 1260, 1180, 1020 cm 1 Preparation 26 1-(6-Decyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide IR (Nujol) . 1780, 1620, 1190, 1000 cm 1 Preparation 27 1-(6-Hexyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide IR (Nujol) . 1780, 1610, 1190 cm 1 NMR (DMSO-d6, d) . 0.89 (3H, t, J=6.7Hz), 1.2-1.6 (6H, m), 1.79 (2H, m), 4.12 (2H, t, J=6.5Hz), 7.24 (1H, dd, J=9.OHz and 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.41 (1H, t, J=8Hz), 7.54 (1H, t, J=8Hz), 7.72 (1H, d, J=8Hz), 7.88 (1H, d, J=8.7Hz), 7.90 (1H, d, J=8.7Hz), 7.97 (1H, d, J=8Hz), 8.02 (1H, d, J=9.OHz), 8.51 (1H, s) Preparation 28 1-(6-Dodecyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1620, 1190, 1030, 730 cm 1 NMR (DMSO-d6, d) . 0.85 (3H, t, J=6.7Hz), 1.2-1.3 (18H, m), 1.78 (2H, m), 4.11 (2H, t, J=6.5Hz), 7.22 (1H, dd, J=9.OHz and 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.40 (1H, t, J=8Hz), 7.55 (1H, t, .~... ..- .-.,~.,..~.~-~"u:~....- ,.., , . ~u~~ew,~.;-~.- ~-,..~-. , 2~~'~~~~~
J=8Hz), 7.73 (1H, d, J=8Hz), 7.85 (1H, d, J=8.7Hz), 7.93 (1H, d, J=8.7Hz), 7.99 (1H, d, J=8Hz), 8.00 (1H, d, J=9.OHz), 8.51 (1H, s) Preparation 29 1-C6-(3,7-Dimethyloctyloxy)-2-naphthoyl]-1H-benzatriazole-3-oxide IR (Nujol) . 1780, 1620, 1190 cm 1 Preparation 30 1-C(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienoyl]-1H-benzotriazole-3-oxide IR (Neat) . 2900, 1780, 1620, 1420, 1070 cm-1 Preparation 31 3,7-Dimethyl-6-octenyl bromide was obtained according to a similar manner to that of Preparation 17.
IR (Neat) . 2900, 1440, 1380 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, d, J=6.3Hz), 1.0-1.5 (2H, m), 1.57 (3H, s), 1.65 (3H, s), 1.7-2.1 (5H, m), 3.4-3.7 (2H, m), 5.08 (1H, m) Preparation 32 To a suspension of sodium hydride (2.04 g) in N,N-dimethylformamide (50 ml) was added 4-hydroxypyridine (5 g) at room temperature. Octyl bromide (9.08 ml) was added thereto. The mixture was stirred for 2 hours at 50°C. The reaction mixture was added to a mixture of brine (100 ml), trtrahydrofuran (100 ml) and ethyl acetate (100 ml). The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the~filtrate was evaporated under reduced pressure to give 1-octyl-4-pyridone (14.? g).
NMR (DMSO-d6, d) . 0.86 (3H, t, J=6Hz), 1.1-1.4 (lOH, m), 1.4-1.8 (2H, m), 3.81 (2H, t, J=7Hz), ..-...._.._."...._.~....~. .~7 . . . --...~---... .. ~--~.~~....."~.~~,.~.~._.,~,~---:.~.:~~~",..~.~.-s.

6.05 (2H, d, J=8Hz), 7.63 (2H, d, J=8Hz) Preparation 33 To a solution of 1-octyl-4-pyridone (10.9 g) in pyridine (100 ml) was added phosphorous pentasulfide (8.65 g) at room temperature. The mixture was stirred for 3 hours at 80°C. The reaction mixture was added to a mixture of water (200 ml) and methylene chloride (200 ml).
The organic layer was separated and dried over magnesium .
sulfate. The magnesium sulfate was filtered off, and the filtrate was evaparated gander reduced pressure to give 1-octyl-1,4-dihydropyridine-4-thione (5.27 g).
IR (Neat) . 2910, 2850, 1620, 1460, 1110 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6Hz), 1.1-1.4 (lOH, m), 1.5-1.9 (2H, m), 3.95 (2H, t, J=7Hz), 7.13 (2H, d, J=7Hz), 7.60 (2H, d, J=7Hz) The following compounds (Pre arations 34 to 36) were obtained according to a similar manner to that of Preparation 1.
Pre~~aration 34 Methyl 2-(4-hydroxyphenyl)-2-methoxyacetate IR (Nujol) . 3350, 1740, 1610, 1600, 1220, 1100 cm 1 NMR (DMSO-d6, d) . 3.23 (3H, s), 3.60 (3H, s), 4.73 (1H, s), 6.72 (2H, d, J=8.9Hz), 7.15 (2H, d, J=8.9Hz) EI-MS (e/z) = 196 (M+) Preparation 35 D-Tyrosine methyl ester hydrochloride IR (Nujol) . 3300, 1740, 1220 cm 1 NMR (DMSO-d6, d) . 3.02 (2H, m), 3.67 (3H, s), 4.16 (1H, t, J=6.7Hz), 6.72 (2H, d, J=8.4Hz), 7.01 (2H, d, J=8.4Hz), 8.58 (2H, s), 9.47 (1H, s) Preparation 36 Methyl (4-hydroxyphenyl)glyoxylate IR (Nujol) . 3380, 1730, 1700, 1600, 1580, 1220 cm-1 NMR (DMSO-d6, d) . 3.91 (3H, s), 6.94 (2H, d, J=8.8Hz), 7.83 (2H, d, J=8.8Hz), 10.9 (1H, S) Preparation 37 N-(t-Butoxycarbonyl)-D-tyrosine methyl ester was obtained according to a similar manner to that of Preparation 2.
IR (Nujol) . 3360, 1700, 1680, 1290, 1270, 1250 cm 1 NMR (DMSO-d6, d) . 1.33 (9H, s), 2.73 (2H, m), 3.59 (3H, s), 4.05 dlH, m), 6.65 (2H, d, J=8.4HZ), 7.00 (2H, d, J=8.4Hz), 7.23 (1H, d, J=7.9HZ), 9.23 (1H, s) Preparation 3 8 To a solution of L-tyrosine methyl ester hydrochloride (1 g) in water (1.5 ml) was added sodium bicarbonate (0.363 g) under ice-cooling and stirred for 10 minutes, and then acetonitrile (7 ml), 37~ formaldehyde aqueous solution (0.637 ml) and sodium cyanoborohydride (0.182 g) was added thereto at -5°C. The mixture was stirred for 2 hours at -5°C. The resultant insoluble material was Filtered off, and the filtrate was extracted with ethyl acetate. The organic layer was separated and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give N,N-dimethyl-L-tyrosine methyl ester (0.21 g).
IR (Nujol) . 1730, 1260, 1010 cm 1 NMR (DMSO-d6, d) . 2.24 (6H, s), 2.72 (2H, m), 3.34 (1H, m), 3.53 (3H, s), 6.64 (2H, d, J=8.4Hz), 6.97 (2H, d, J=8.4Hz), 9.18 (1H, s) The following compounds (Preparations 39 to 44) were - ~o -~~4~"~~~
obtained according to a similar manner to that of Preparation 3.
Preparation 39 Methyl 2-(4-octyloxyphenyl)acetate IR (Neat) . 2910, 2850, 1730, 1240 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.3Hz), 1.2-1.5 (lOH, m), 1.6-1.9 (2H, m), 3.58 (2H, s), 3.59 (3H, s), 3.92 (2H, t, J=6.4Hz), 6.85 (2H, d, J=8.7Hz), 7.15 (2H, d, J=8.7Hz) Preparation 40 Ethyl 3-(4-octyloxyphenyl)propionate IR (Neat) . 2920, 2850, 1730, 1240 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.7Hz), 1.15 (3H, t, J=7.lHz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 2.55 (2H, t, J=7.2Hz), 2.77 (2H, t, J=7.2Hz), 3.90 (2H, t, J=6.4Hz), 4.03 (2H, q, J=7.lHz), 6.81 (2H, d, J=8.6Hz), 7.11 (2H, d, J=8.6Hz) Preparation 41 Methyl 2-(4-octyloxyphenyl)-2-methoxyacetate IR (Neat) . 2910, 2850, 1740, 1600, 1240, 1100 cm 1 NMR (DMSO-d6, b) . 0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m); 1.6-1.8 (2H, m), 3.26 (3H, s), 3.62 (3H, s), 3.94 (2H, t, J=6.4Hz), 4.83 (1H, s), 6.91 (2H, d, J=8.7Hz), 7.27 (2H, d, J=8.7Hz) EI-MS (e/z) = 308 (M+) Preparation 42 04-Octyl-N-(t-butoxycarbonyl)-D-tyrosine methyl ester IR (Nujol) . 3350, 1730, 1680, 1510, 1240, 1160 cm 1 NMR (DMSO-d6, d,) . 0.86 (3H, t, J=6.7Hz), 1.2-1.3 (lOH, m), 1.68 (2H, m), 2.82 (2H, m), 3.60 (3H, s), 3.91 (2H, t, J=7.3Hz), 4.08 (1H, m); 6.81 °

2~4a7~~
(2H, d, J=8.6Hz), 7.12 (2H, d, J=8.6Hz), 7.25 (1H, d, J=B.OHz) Preparation 43 04-Octyl-N,N-dimethyl-L-tyrosine methyl ester IR (Neat) . 2930, 2860, 1730, 1250 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.6Hz), 1.26 (lOH, m), 1.68 (2H, m), 2.80 (2H, m), 3.33 (6H, s), 3.37 (1H, m), 3.53 (3H, s), 3.89 (2H, t, J=6.4Hz), 6.79 (2H, d, J=8.6Hz), 7.08 (2H, d, J=8.6Hz) Preparation 44 Methyl (4-octyloxyphenyl)glyoxylate IR (Neat) . 2930, 2850, 1730, 1670, 1600, 1260, 1210, 1160 cm NMR (DMSO-d6, 8) . 0.86 (3H, t, J=6.3Hz), 1.2-1.5 (lOH, m), 1.6-1.9 (2H, m), 3.93 (3H, s), 4.10 (2H, t, J=6.5Hz), 7.12 (2H, d, J=8.9Hz), 7.92 (2H, d, J=8.9Hz) The following compounds (Preparations 45 to 51) were obtained according to a similar manner to that of Preparation 4.
Preparation 45 4-(2-Butoxyethoxy)benzoic acid IR (Nujol) . 1670, 1610, 1260 cm 1 NMR (DMSO-d6, d) . 0.87 (3H, t, J=7.2Hz), 1.2-1.6 (4H, m), 3.45 (2H, t, J=6.4Hz), 3.70 (2H, t, J=4.4Hz), 4.16 (2H, t, J=4.4Hz), 7.02 (2H, d, J=8.9Hz), 7.88 (2H; d, J=8.9Hz), 12.63 (1H, s) Preparation 46 2-(4-Octyloxyphenyl)acetic acid _ ~2 _ IR (Nujol) . 1680, 1240, 820, 780 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.8Hz), 1.1-1.5 (lOH, m), 1.6-1.8 (2H, m), 3.47 (2H, s), 3.92 (2H, t, J=6.4Hz), 6.84 (2H, d, J=8.6Hz), 7.14 (2H, d, J=8.6Hz) Pr~e.aration 47 3-(4-Octyloxyphenyl)propionic acid IR (Nujol) . 1680, 1500, 1200 cm-1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.3Hz), 1.1-1.5 (lOH, m), 1.6-1.8 (2H, m), 2.47 (2H, t, J=7.2Hz), 2.74 (2H, t, J=7.2Hz), 3.90 (2H, t, 3=6.4Hz), 6.81 (2H, d, J=8.6Hz), 7.11 (2H, d, 3=8.6Hz), 12.10 (1H, br S) Preparation 48 2-(4-Octyloxyphenyl)-2-methoxyacetic acid IR (Nujol) . 1760, 1720, 1600, 1500, 1240, 1180, 1100, 830 cm 1 NMR (DMSO-d6, 8) . 0.86 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m), 2.6-2.8 (2H, m), 3.26 (3H, s), 3.94 (2H, t, J=6.4Hz), 4.67 (1H, s), 6.90 (2H, d, J=8.6Hz), 7.27 (2H, d, J=8.6Hz) Preparation 49 04-Octyl-N-(t-butoxycarbonyl)-D-tyrosine IR (Nujol) . 3400-29'00,.1700, 1500 , 1240, 1160 cm 1 NMR (DMSO-d6, d) . 0.859 (3H, t, J=6.8Hz), 1.20-1.30 (10H, m), 1.32 (9H, s), 1.68 (2H, m), 2.67-2.95 (1H, m), 3.90 (2H, t, J=7Hz), 4.01 (1H, m), 6.81 (2H, d, J=8.6Hz), 7.02 (1H, d, J=8.3Hz), 7.13 (2H, d, J=8.6Hz) Preparation 50 04-Octyl-N,N-dimethyl-L-tyrosine . IR (Neat) . 2940, 2860, 2600, 1620, 1240 cm 1 NMR (DMSO-d6, 8) . 0.86 (3H, t, J=6.6Hz), 1.26 (lOH, m), 1.68 (2H, m), 2.67 (6H, s), 2.8-3.6 (3H, m), 3.91 (2H, t, J=6.4Hz), 6.85 (2H, d, J=8.5Hz), 7.16 (2H, d, J=8.5Hz) Preparation 51 04-Octyloxyphenyl)glyoxylic acid IR (Neat) . 1730, 1670, 1600, 1260, 1160 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.65-1.85 (2H, m), 4.09 (2H, t, J=6.5Hz), 7.12 (2H, d, J=8.9Hz), 7.89 (2H, d, J=8.9Hz) preparation 52 NT-Octyl-N-(t-butoxycarbonyl)-L-histidine was obtained from N-(t-butoxycarbonyl)-L-histidine methyl ester according to similar manners to those of Preparations 3 and 4.
NMR (DMSO-d6, d) . 0.85 (3H, t, J=6.3Hz), 1.23 (lOH, m), 1.35 (9H, s), 2.83 (2H, m), 3.90 (2H, t, J=7Hz), 4.0-4.2 (1H, m), 6.36 (1H, s), 7.02 (1H, d, J=8Hz), 7.75 (1H, s) The following compounds (Preparations 53 to 60) were obtained according to a similar manner to that of Preparation 11.
Preparation 53 4-Octyloxyphthalic acid IR (Neat) . 2930, 2860, 2500, 1700, 1600, 1260 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.5-1.8 (2H, m), 4.05 (2H, t, J=6.2Hz), 7.03 (1H, d, J=2.6Hz), 7.06 (1H, dd, J=8.4Hz and 2.6Hz), 7.72 (1H, d, J=8.4Hz) 2a~~=~~
Preparation 54 3-Methoxy-4-octyloxybenzoic acid IR (Nujol) . 2600, 1680, 1600, 1270, 1230 cm NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 3.80 (3H, s), 4.01 (2H, t, J=6.5Hz), 7.03 (1H, d, J=8.5Hz), 7.44 (1H, d, J=l.9Hz), 7.54 (1H, dd, J=8.5Hz and l.9Hz) Preparation 55 4-(4-Octyloxyphenyl)benzoic acid TR (Nujol) . 1670, 1600, 830, 770 cm 1 NMR (DMSO-d6, d) . 0.87 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 4.01 (2H, t, J=6.4Hz), 7.04 (2H, d, J=8.8Hz), 7.68 (2H, d, J=8.8Hz), 7.75 (2H, d, J=8.5Hz), 7.99 (2H, d, J=8.5Hz) Preparation 56 6-(2-Ethylhexyloxy)-2-naphthoic acid IR (Nujol) . 1660, 1610, 1280, 1200 cm 1 NMR (DMSO-d6, d) . 0.88 (3H, t, J=7.3Hz), 0.92 (3H, t, J=7.3Hz), 1.2-1.6 (8H, m), 1.7-1.9 (1H, m), 4.01 (2H, d, J=5.7Hz), 7.23 (1H, dd, J=8.9 and 2.4Hz), 7.42 (1H, d, J=2.4Hz), 7.86 (1H, d, J=8.7Hz), 7.94 (1H, d, J=8.7Hz), 8.01 (1H, d, J=8.9Hz), 8.51 (1H, s), 12.9 (1H, s) Preparation 57 6-(3,7-Dimethyl-6-octenyloxy)naphthoic acid IR (Nujol) . 1660, 1610, 1290, 1200 cm NMR (DMSO-d6, d) . 0.95 (3H, d, J=6.lHz), l.l-1.5 (2H, m), 1.57 (3H, s), 1.64 (3H, s), 1.6-2.1 (5H, m), 4.15 (2H, t, J=6.7Hz), 5.10 (1H, t, J=7.lHz), 7.22 (1H, dd, J=8.9Hz and 2.3Hz), 7.42 (1H, d, J=2.3Hz), 7.86 (1H, d, J=8.6Hz), 7.94 (1H, d, J=8.6Hz), 8.01 (1H, d, J=8.9Hz), 8.52 (1H, s), 12.89 (1H, s) Preparation 58 6-(3,7-Dimethyl--2,6-octadienyloxy)naphthoic acid IR (Nujol) . 1660, 1620, 1210 cm 1 NMR (DMSO-d6, b) . 1.57 (3H, s), 1.60 (3H, s), 1.76 (3H, s), 2.07 (4H, m), 4.70 (2H, d, J=6.5Hz), 5.07 (1H, m), 5.51 (1H, t, J=6.5Hz), 7.24 (1H, dd, J=8.9Hz and 2.4Hz), 7.41 (1H, d, J=2.4Hz), 7.85 (1H, d, J=8.7Hz), 7..94 (1H, d, J=8.7Hz), 8.01 (1H, d, J=8.9Hz), 8.52 (1H, s), 12.88 (1H, s) Preparation 59 (2H)-3-(4-Octyloxyphenyl)acrylic acid IR (Nujol) . 1660., 1600, 1240 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 4.00 (2H, t, J=6.4Hz), 6.36 (1H, d, J=l6Hz), 6.95 (2H, d, J=8.7Hz), 7.54 (1H, d, J=l6Hz), 7.61 (2H, d, J=8.7Hz), 12.20 (1H, br s) Preparation 60 Sodium 6-octyloxy-2-naphthalene sulfonate IR (Nujol) . 1230, 1180, 860, 820 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6Hz), 1.1-1.6 (lOH, m), 4.06 (2H, t, J=5Hz), 7.08 (1H, d, J=9Hz), 7.21 (1H, s), 7.79 (1H, d, J=9Hz), 8.00 (1H, s) Preparation 61 To a solution of thionyl chloride (0.692 ml) and N,N-dimethylformamide C0.022 ml) was added sodium 6-octyloxy-2-naphthalenesulfonate (1 g) under ice-cooling and stirred for 1.5 hours at 95°C. The reaction mixture was evaporated under reduced pressure to give 6-octyloxy-2-naphthylsulfonyl chloride (1 g).
IR (Nujol) . 1610, 1260, 1160 cm ~' NMR (CDC13, d) ., 0.90 (3H, t, J=6.2Hz), 1.2-1.7 (lOH, m), 1.8-2.0 (2H, m), 4.12 (2H, t, J=6.5Hz), 7.20 (1H, d, J=2.2Hz), 7.32 (1H, dd, J=9.OHz and 2.2Hz), 7.84-7.97 (3H, m), 8.49 (1H, s) The following compounds (Preparations 62 to 71) were obtained according to a similar manner to that of Preparation 12.
Preparation 62 1-(4-Octylbenzoyl)-1H-benzotriazole-3-oxide IR (Neat) . 2930, 2850, 1780, 1610, 1240, 990 cm 1 Preparation 63 1-[4-(4-Octyloxyphenyl)benzoyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1600, 980 cm 1 Preparation 64 1-[6-(2-Ethylhexyloxy)-2-naphthoyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1620, 1270, 1180 cm 1 Nl~.t (CDC13, 8) . 0.93 (3H, t, J=7.lHz), 0.98 (3H, t, J=7.4Hz), 1.3-1.7 (8H, m), 1.7-2.0 (1H, m), 4.03 (2H, d, J=5.7Hz), 7.22 (1H, d, J=2.2Hz), 7.29 (1H, dd, J=8.9Hz, 2.2Hz), 7.4-7.7 (3H, m), 7.87 (1H, d, J=9.5Hz), 7.92 (1H, d, J=9.5Hz), 8.1-8.2 (2H, m), 8.80 (1H, s) 2~~~~~~~
Preparation 65 1-[6-(3,7-Dimethyl-6-octenyloxy)-2-naphthoyl]-1H-benzotriazole-3-oxide IR (Neat) . 2900, 1770, 1620, 1180 cm 1 Preparation 66 1-[6-~(E)-3,7-Dimethyl-2,6-octadienyloxy}-2-naphthoyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1620, 1270, 1180 cm 1 Preparation 67 1-(2-Anthrylcarbon~~1)-1H-benzotriazole-3-oxide IR (Nujol) . 1780, 1200, 720, 740 cm ~' Preparation 68 1-[2-(4-Octyloxyphenyl)acetyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1730, 1460, 1420, 1250, 1130 cm 1 Preparation 69 1-[3-(4-Octyloxyphenyl)propionyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1730, 1420, 1340, 1240, 950 cm 1 Preparation 70 1-[(E)-3-(4-Octyloxyphenyl)acryloyl]-1H-benzotriazole-3-oxide IR (Nujol) . 1770, 1600, 1260, 1080 cm 1 Preparation 71 1-(04-Octyl-N,N-dimethyl-L-tyrosyl)-1H-benzotriazole-3-oxide IR (Neat) - 2930, 2850, 1800, 1610 cm 1 _ 78 _ Preparation 72 To a suspension of lithium aluminum hydride (4.05 g) in tetrahydrofuran (475 ml) was added dropwise a solution of 4-octyloxybenzaldehyde (25 g) in tetrahydrofuran (25 ml) at 55 ~ 60°C. The reaction mixture was stirred under reflex for 1 hour, and thereto was added sodium fluoride (35.84 g) and water (11.52 ml) under ice-cooling. The mixture was stirred for 30 minutes, and filtrated. The filtrate was evaporated in vacuo to give 4-octyloxybenzyl alcohol (25.1 g) as crystals.
IR (Nujol) . 3200, 1605, 1510 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.7Hz), 1.26-1.38 (lOH, m), 1.62-1.72 (2H, m), 3.92 (2H, t, J=6.5Hz), 4.40 (2H, d, J=5.7Hz), 5.03 (1H, t, J=5.7Hz), 6.85 (2H, d, J=8.6Hz), 7.20 (2H, d, J=8.6Hz) Preparation 73 To a suspension of 4-octyloxybenzyl alcohol (25 g), N-hydroxyphthal3mide (17.15 g) and triphenylphosphine (27.74 g) in tetrahydrofuran (250 ml) was. added dropwise diethyl azodicarboxylate (18.4 g) under ice-cooling. The reaction mixture was stirred at room temperature for 2 hours, and evaporated in vacuo. The residue was purified by chromatography on silica gel to give N-(4-octyloxybenzyloxy)phthalimide (33.45 g) as crystals.
IR (Nujol) . 1780, 1725, 1605, 1580, 1505 cm 1, NMR (DMSO-d6, 8) . 0.86 (3H, m), 1.26 (lOH, m), 1.70 (2H, m), 3.95 (2H, t, J=6.5Hz), 5.08 (2H, s), 6.93 (2H, d, J=8.6Hz), 7.40 (2H, d, J=8.6Hz), 7.85 (4H, s) Preparation 74 To a solution of N-(4-octyloxybenzoyloxy)phthalimide (4.13 g) in tetrahydrofuran (16 ml) was added _ 79 -2~~'~'~ ~~~~
hydrazine-hydrate (0.53 ml) at room temperature. After the mixture was stirred at the same temperature for 1 hour, the precipitate was filtered off. To the filtrate was added water (6 ml) and 4-hydroxyphenylglyoxylic acid (1.5 g) at room temperature. The mixture was maintained at pH 44.5 with aqueous sodium bicarbonate solution for 2 hours, thereto was added ethyl acetate, and adjusted to pH
2 with 1N hydrochloric acid. The separated organic layer was washed with brine, and dried over magnesium sulfate.
The organic solvent was evaporated in vacuo to give 2-(4-hydroxyphenyl)-2-(4-octyloxybenzyloxyimino)acetic acid (3.4 g).
IR (Nujol) . 3400, 1715, 1605, 1590, 1505 cm ~' NMR (DMSO-d6, d) . 0.86 (3H, m), 1.25 (lOH, m), 1.69 (2H, m), 3.94 (2H, t, J=6.4Hz), 5.07 (2H, s), 6.82 (2H, d, J=8.7Hz), 6.90 (2H, d, J=8.6Hz), 7.29 (2H, d, J=8.6Hz), 7.35 (2H, d, J=8.7Hz) The following compounds (Preparations 75 and 76) were obtained according to a similar manner to that of Preparation 74.
Preparation 75 2-Phenyl-2-(4-octyloxybenzyloxyimino)acetic acid IR (Nujol) . 1720, 1610, 1585, 1515 cm NMR (DMSO-d6, 8) . 0.86 (3H, t, J=6.7Hz), 1.26 (lOH, m), 1.69 (2H, m), 3.9'4 (2H, t, J=6.5Hz), 5.13 (2H, s), 6.91 E2H, d, J=8.6Hz), 7.22-7.49 (7H, m) Preparation 76 2-(4-Octyloxybenzyloxyimino)acetic acid IR (Nujol) . 1700, 1670, 1600 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.2Hz), 1.26 (lOH, m), 1.70 (2H, m), 3.95 (2H, t, J=6.5Hz), 5.13 (2H, s); 6.91 (2H, d, J=8.6Hz), 7.29 (2H, d, _ 80 -J=8.6Hz), 7.56 (1H, s) Preparation 77 A solution of 4-octyloxyphenylglyoxylic acid (0.935 g) in a mixture of water (9 ml) and tetrahydrofuran (18 ml) and adjusted to pH 3.5-4 with 1N hydrochloric acid and methoxyamine hydrochloride (0.337 g) was added thereto at room temperature. The mixture was stirred for 2 hours at room temperature maintaining pH 3.54 with 1N hydrochloric acid. The reaction mixture was added to ethyl acetate.
The organic layer was separated and dried over magnesium sulf ate . The magnesium sulf ate was filtered of f , and the filtrate was evaporated under reduced pressure to give 2-(4-octyloxyphenyl)-2-methoxyiminoacetic acid (0.57 g).
IR (Nujol) . ~ 1700, 1600, 1250, 1030 cm 1 NI~t (DMSO-d6, 8) . 0.86 (3H, t, J=6.3Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 3.89 (3H, s), 3.99 (2H, t, J=6.4Hz), 7.00 (2H, d, J=8.9Hz), 7.45 (2H, d, J=8.9Hz), 14.05 (1H, s) Preparation 78 To a mixture of 2,3,4,5,6-pentafluorobenzoic acid (1 g) and 2,2,3,3,4,4,5,5-octafluoropentanol (1.18 g) in N,N-dimethylformamide (5 ml) was added 62% sodium hydride (0.39 g) at room temperature. The mixture was stirred at the same temperature for 1 hour, and thereto was added a mixture of water and ethyl acetate. The separated organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by chromatography on silica gel to give 4-(2,2,3,3,4,4,5,5-octafluoropentyloxy)-2,3,5,6-tetra-fluorobenzoic acid (923.0 mg).
IR (Nujol) . 1700, 1580 cm 1 NMR (DMSO-d6, d) . 4.96 (2H, t, J=14.2Hz), 7.10 (1H, tt, J=5.6Hz and 50.2Hz) ~~4'~z~
Preparation 79 4-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluoro-octyloxy)-2,3,5,6-tetrafluorobenzoic acid IR (Nujol) . 3400, 1640, 1560 cm 1 NMR (DMSO-d6, 8) . 4.95 (2H, t, J=14.OHz) The following compounds (Preparations 80 to 90) were obtained according to a similar manner to that of Preparation 5.
Preparation 80 Succinimido 2-(4-hydroxyphenyl)-2-(4-octyloxybenzyl-oxyimino)acetate IR (Nujol) . 1800, 1770, 1700, 1600 cm 1 Preparation 81 Succinimido 2-phenyl-2-(4-octyloxybenzyloxyiminol-acetate IR (Nujol) . 1780, 1730, 1605 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, m), 1.26 (lOH, m), 1.69 (2H, m), 2.90 (4H, m), 3.94 (2H, t, J=6.4Hz), 5.30 (2H, s), 6.91 (2H, d, J=8.6Hz), 7.25-7.56 (7H, m) Preparation 82 Succinimido 2-(4-Octyloxybenzyloxyimino)acetate IR (Nujo1) . 1760, 1725, 1600, 1580 cm 1 NMR (DMSO-d6, 8) . 0.86 (3H, t, J=6.7Hz), 1.26 (lOH, m), 1.70 (2H, m), 2.85 (4H, s), 3.96 (2H, m), 5.28 (2H, s), 6.91 (2H, d, J=8.6Hz), 7.33 (2H, d, J=8.6Hz), 8.12 (1H, s) Preparation 83 Succinimido 4-(2,2,3,3,4,4,5,5-octafluoropentyloxy)-2,3,5,6-tetraflurobenzoate °

- 82 _ ~~~7~~
IR (Nujol) . 3500, 1770, 1740, 1640 cm 1 NMR (DMSO-d6, d) . 2.90 (4H, s), 5.23 (2H, t, J=13.8Hz), 7.11 (1H, tt, J=50.2Hz and 5.6Hz) Preparation 84 Succinimido 4-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctylo~y)-2,3,5,6-tetrafluorobenzoate IR (Nujol) . 1735, 1620, 1600 cm-1 NMR (DMSO-d6, 8) . 2.90 (4H, s), 5.12 (2H, t, J=13.8Hz) Preparation 85 Succinimido 3-methoxy-4-octyloxybenzoate IR (Nujol) . 1760, 1730, 1600, 1280, 1200, 880 cm-1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m.), 1.6-1.9 (2H, m), 2.88 (4H, s), 3.84 (3H, s), 4.09 (2H, t, J=6.5Hz), 7.19 (1H, d, J=8.6Hz), 7.49 (1H, d, J=2.OHz), 7.73 (1H, dd, J=8.6 and 2.OHz) Preparation 86 Succinimido 4-(2-butoxyethoxy)benzoate IR (Nujol) . 1730, 1600, 1250, 1060 cm 1 NMR (DMSO-d6, d) . 0.87 (3H, t, J=7.2Hz), 1.2-1.6 (4H, m), 2.89 (4H, s), 3.46 (2H, t, J=6.3Hz), 3.73 (2H, t, J=4.4Hz), 4.25 (2H, t, J=4.4Hz), 7.18 (2H, d, J=9.OHz), 8.04 (2H, d, J=9.OHz) Preparation 87 Succinimido 2-(4-Octyloxyphenyl)-2-metho~yaaetate IR (Nujol) . 1810, 1740, 1610, 1250, 1210, 1100 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.7Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 2.80 (4H, s), 3.35 (3H, s), 3.97 (2H, t, J=6.4Hz), 5.35 (1H, s), 6.96 (2H, d, J=8.?Hz), 7.38 (2H, d, J=8.7Hz) - $~ - 20~~'~~~~
Preparation 88 04-Octyl-N-(t--butoxycarbonyl)-D-tyrosine succinimido ester IR (Nujol) . 3370, 1780, 1730, 1700, 1250, 1200 cm 1 Preparation 89 Succinimido 2-(4-octyloxyphenyl)-2-methoxyiminoacetate IR (Nujol) . 1800, 1780, 1730, 1600, 1250, 1180, 1130 cm 1 NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.6Hz), 1.2-1.5 (lOH, m), 1.6-1.8 (2H, m), 2.89 (4H, s), 4.01 (3H, s), 4.03 (2H, t, J=6.4Hz), 7.08 (2H, d, J=8.9Hz), 7.68 (2H, d, J=8.9Hz) Preparation 90 NT-Octyl-N-(t-butoxycarbonyl)-L-histidine succinimido ester IR (Neat) . 1810, 1780, 1730, 1500, 1360, 1200, 1160 cm-1 Preparation 91 4-Octyloxyphthalic anhydride was obtained from 4-octyloxyphthalic acid according to a similar manner to that of Preparation 5.
IR (Neat) . 2910, 2850, 1840, 1760, 1640, 1610, 1290, 1260 cm ~' NMR (DMSO-d6, d) . 0.86 (3H, t, J=6.8Hz), 1.2-1.5 (lOH, m), 1.6-1.9 (2H, m), 4.19 (2H, t, J=6.5Hz), 7.47 (1H, dd, J=8.4Hz and 2.2Hz), 7.57 (1H, d, J=2.2Hz), 7.98 (1H, d, J=8.4Hz) 2~~~'~r~
Pr~aration 92 N-Octyloxycarbonyloxysuccinimide was obtained according to a similar manner to that of Pr ~aration 5.
IR (Neat) . 2960, 2850, 1780, 1740, 1260, 1230 cm NMR (CDC13, 8) . 0.89 (3H, t, J=6.7Hz), 1.2-1.4 (10H, m), 1.6-1.8 (2H, m), 2.84 (4H, s), 4.32 (2H, t, J=6.7Hz) Preparation 93 To a ~o:Lution of octyl phenyl ether (1.53 g) in chloroform (6 ml) was added chlorosulfonic acid at 0°C.
The mixture was stirred at room temperature for 30 minutes, then the mixture was poured into a mixture of water and tetrahydrofuran.
The separated organic layer was washed with sodium chloride aqueous solution, dried over magnesium sulfate and then the solvent was evaporated in vacuo. The residue was subjected to a column chromatography on silica gel to give 4-octyloxyphenylsulfonyl chloride (1.25 g).
IR (Nujol) . 1600, 1580, 1500, 1380, 1180 cm NMR (CDC13, 8) . 0.89 (3H, t, J=6.6Hz), 1.20-1.50 (lOH, m), 1.80 (2H, m), 4.06 (2H, t, J=6.4Hz), 7.03 (2H, d, J=9.OHz), 7.96 (2H, d, J=9.OHz) The following compounds (Preparations 94 and 95) were obtained according to a similar manner to that of Prep-aration ~
Preparation 94 Succinimido 4-(4-heptyloxyphenyl)benzoate IR (Nujol) . 1760, 1740, 1600 cm-1 NMR (CDC13, 8) . 0_87 (3H, t, J=6.8 Hz), 1.2-1.7 (8H, m), 1.7-1.9 (2H, m), 2.92 (4H, S), 4.01 (2H, t, J=6.5 Hz), 7.00 (2H, d, J=8.8 Hz), 7.58 (2H, d, J=8.8 Hz), 7.69 (2H, d, J=8.5 Hz), 8.17 (2H, d, J=8.5 Hz) - 84a -Preparation 95 Succinimido 4-(4-hex~rloxyphenoxg)benzoate IR(Nujol) . 1760, 1720, 1600 cm NNaR (CDC13, d) . 0.92 (3H, t, J=6.8 Hz), 1.2-1.5 (6H, m), 1.7-1.9 (2H, m), 2.90 (4H, s), 3.96 (2H, t, J=6.5 Hz), 6.9-7.1 (6H, m), 8.07 (2H, d, J=9 Hz) In the following, the structures of the compounds of Examples 13 to 53 are shown.
HO OH
HO
NH
H3C , NH-R
N O
H.
O
IL
Na0-S-ll O
In the following formulae, tBu means t-butyl, and p-TsOH means p-toluenesulfonic acid.
ExampleCompound R

No. No.
13 FR139835 - COO(GH2)7CH3 14 FR139537 -CO ~ ~ -tBu 15 FRI41145 -CO ~ ~ -O(CH2)20(CH2)3CH3 16 FR139538 -CO ~ ~ -O(CH2)4- /

_ g~
Example Compound R
No, No.
_C~_ / ~ O(CH2)7CH3 COON
-CO- / ~ -O(CH2)7CH3 F F
19 FR140727 -CO / ~ -OCH2(CF2)4H
F F
F F
FR143301 -CO- / ~ OCH2(CF2)6CF3 F F

22 FR139503 -COCH / ~ O(CH2)7CH3 NHCOOtBu 23 FR139500 -COCHCH2 ~ ~ -O(CH2)7CH3 (D) NHCOO -Bu (L) _ 87 _ Example Compound No. No.

NHCOOtHu 25 FR139502-COCHCH2-' ~ "(CH2)7CH3 (L) N

S

II
-CO-C / ~ -O(CH2)7CH3 ,O-CH2 / ~ -O(CH2)7CH3 S

It -CO-C / ~ OH

O-CH2 / ~ O (CH2 ) 7GH3 S

It -CO-C

O-CH2 / ~ -O(CH2)7CH3 S

II

-CO-CH

31 FR140731-CO / ~-(CH2)7CH3 32 FR140217-CO / ~ -O /_~ -O(CH2)7CH3 _ 88 _ 2~~~'~~a Example Compound R
PIo. No.
33 FR142472 -CO-~ ~ ~ \ O(CH2)7CH3 -CO_ / \
34 FR140496 ~ O(CH2)3CH3 -CO /
35 FR140497 \ -O(CH2)5CH3 -CO ~ \
36 FR143483 \ O
-CO ~ \
37 FR140728 ~ O(CH2}9CH3 -CO l \
38 FR142172 \ -O
-CO ~ ~ ~ ~ '~
39 FR143326 \
CO /
40 FR142390 \ -O
-CO /
41 FR140729 ~ O(CH2)11CH3 8g Example CompoundR

No. No.

43 FR143020-COCH2 / \ -O(CH2)7CH3 44 FR143021-CO(CH2)2- / \ O(CH2)7VCH3 \ / \ -O(CH2)7CH3 N(CH3)2 / \
C

-CO-O(CH2)7CH3 47 FR141564-S02- / ~ O(CH2)7CH3 48 FR143170S02 / \
\ O(CH
) CH

NH2 p-TsOH .

49 FR138912-CO-CHCH2-/ \ O(CH2)7CH3 (L) ' Br ~ .

50 FR138960//~\\ 0 -COCH2S-( ,N-(CH2)7CH3 C

H / \ O(CH2)7CH3 (D) y 90 -20~~'~~~a ExampleCompoundR
No. No.

NH2 p-TsOH

-CO-CHCH2- ~ ~ O(CH2)7CH3 (L) . Br ~

53 FR138960.-COCH2S ~ ~ N=(CH2)7CH3 Example 13 FR139835 substance was obtained by reacting FR133303 substance with N- octyloxycarbonyloxysucc;n;m;de according to a similar manner to that of Example 3.
TR (Nujol) . 3300, 1620 cm 1 FAB-MS e/z = 1137 (M + Na) Example 14 FR139537 substance was obtained by reacting FR133303 substance with succinimido 4-t-butylbenzoate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 NMR (D20, d) . 1.05 (3H, d, J=6.9Hz), 1.15 (3H, d, J=5.9Hz), 1.33 (9H, s), 2.0-2.3 (3H, m), 2.4-2.6 (3H, m), 2.7-2.9 (1H, m), 3.4-3.6 (1H, m), 3.8-4.9 (12H, m), 5.07 (2H, m), 5.40 (1H, d, J=3Hz), 7.06 (1H, d, J=8.2Hz), 7.08 (1H, dd, J=8.2Hz and 2Hz), 7.27 (1H, d, J=2Hz), 7.60 (1H, d, J=8.6Hz), 7.75 (1H, d, J=8.6Hz) Example 15 FR141145 substance was obtained by reacting FR133303 ~~4~~.~~

substance with succinimido 4-(2-butoxyethoxy)benzoate according to a similar manner to that of Example 3.
TR (Nujol) . 3300, 1620 cm 1 NMR (DMSO-d6, + D20, d) . 0.88 (3H, t, J=7.3Hz), 0.96 (3H, d, J=6.7Hz), 1.04 (3H, d, J=5.7Hz), 1.2-1.6 (4H, m), 1.7-2.0 (3H, m), 2.1-2.65 (4H, m), 3.16 (1H, m), 3.7-4.5 (20H, m), 4.78 (1H, d, J=3Hz), 4.86 (1H, d, J=3.8Hz), 5.02 (1H, d, J=3Hz), 6.74 (1H, d, J=8.2Hz), 6.79 (1H, d, J=8.2Hz), 7.00 (2H, d, J=8.9Hz), 7.06 (1H, s), 7.87 (2H, d, J=8.9Hz) FAB-MS e/z = 1201 (M + Na) Example 16 FR139538 substance was obtained by reacting FR133303 substance with succinimido 4-(4-phenylbutoxy)benzoate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 FAB-MS e/z = 1233 (M + Na) ZO
Example 17 FR140215 substance was obtained by reacting FR233303 substance with 4-octyloxyphthalic anhydride according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 FAB-MS e/z = 1257 (M + Na) Example 18 FR140216 substance was obtained by reacting FR133303 substance with succinimido 3-methoxy-4-octyloxybenzoate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 FAB-MS e/z = 1243 (M + Na) 20~~~~~
Example 19 FR140727 substance was obtained by reacting FR133303 substance with succinimido 4-(2,2,3,3,4,4,5,5-octafluoro-pentyloxy)-2,3,5,6-tetrafluorobenzoate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1630 cm 1 FAB-MS e/z : 1387 (M + Na) Example 20 FR143301 substance was obtained by reacting FR133303 substance with succinimido 4-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecaf luorooctyloxy)-2,3,5,6-tetrafluorobenzoate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1630 cm 1 FAB-MS e/z = 1534 (M+) Example 21 FR140495 substance was obtained by reacting FR133303 substance with succinimido 2-(4-biphenylyl)acetate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 NMR (CD30D, 8) . 1.0-1.1 (6H, m), 1.9-2.2 (3H, m), 2.3-2.6 (3H, m), 2.7-2.85 (1H, m), 3.35 (1H, m), 3.58 (2H, s), 3.65-4.7 (13H, m), 4.93 (1H, d, J=3Hz), 5.04 (1H, d, J=3.8Hz), 5.25 (1H, d, J=3Hz), 6.85 (1H, d, J=8.3Hz), 7.01 (1H, dd, J=8.3Hz and 2Hz), 7.3-7.6 (10H, m) Example 22 FR139503 substance was obtained by reacting FR133303 substance with succinimido 2-(4-octyloxyphenyl)-2-methoxyacetate according to a similar manner to that of Example 3.
IR (Nujol) . 3330, 1620 cm 1 FAS-MS e/z = 1257 (M + Na) Example 23 FR139500 substance was obtained by reacting FR133303 substance with 04-octyl-N-(t-butoxycarbonyl)-D-tyrosine succinimido ester according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 NMR (CD30D, 8) . 0.90 (3H, t, J=6.8Hz), 1.06 (3H, d, J=6.8Hz), 1.17 (3H, d, J=6.7Hz), 1.20-1.30 (10H, m), 1.35 (9H, s), 1.74 (2H, m), 1.9-2.1 (3H, m), 2.45 (3H, m), 2.76 (1H, m), 3.0-3.1 (1H, m), 3.37 (1H, m), 3.7-4.6 (18H, m), 4.94 (1H, d, J=3Hz), 5.01 (1H, d, J=3.8Hz), 5.25 (1H, d, J=3Hz), 6.79 (2H, d, J=8.5Hz), 6.83 (1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2Hz), 7.12 (2H, d, J=8.5Hz), 7.31 (1H, d, J=2Hz) Example 24 FR139501 substance was obtained by reacting FR133303 substance with N-(t-butoxycarbonyl)-L-2-(2-naphthyl)-glycine suecinimido ester according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 Example 25 FR139502 substance was obtained by reacting FR133303 substance with NT-octyl-N-(t-butoxycarbonyl)-L-histidine succinimido ester according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 em 1 FAB-MS e/z = 1330 (M + Na) Example 26 FR138959 substance was obtained by reacting FR133303 substance with succinimido 2-(4-octyloxyphenyl)-2-methoxyiminoacetate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1620 cm 1 NMR (CD30D, d) . 0.91 (3H, t, J=6.6Hz), 1.06 (3H, d, J=6.8Hz), 1.25 (3H, d, J=6.3Hz), 1.25-1.6 (lOH, m), 1.65-1.9 (2H, m), 1.9-2.2 (3H, m), 2.3-2.65 (3H, m), 1.75-1.9 (1H, m), 3.3-3.5 (1H, m), 3.95 (3H, s), 3.7-4.75 (16H, m), 5.03 (1H, d, J=3.OHz), 5.11 (1H, d, J=3.7Hz), 5.46 (1H, d, J=2.7Hz), 6.86 (1H, d, J=8.2Hz), 6.89 (2H, d, J=8.9Hz), 7.01 (1H, dd, J=8.2Hz and 2Hz), 7.31 (1H, d, J=2Hz), 7.54 (2H, d, J=8.9Hz) FAB-MS e/z = 1270 (M + Na) Example 27 FR140291 substance was obtained by reacting FR133303 substance with succinimido 2-(4-hydroxyphenyl)-2-(4-octyloxybenzyloxyimino)acetate according to a similar manner to that of Example 3.
IR (Nujol) . 3250, 1650, 1620 cm 1 FAB-MS e/z = 1363 (M + Na) Example 28 FR141580 substance was obtained by reacting FR133303 substance with succinimido 2-phenyl-2-(4-octyloxy-benzyloxyimino)acetate according to a similar manner to that of Example 3.
IR (Nujol) . 3300, 1646 cm 1 FAB-MS e/z = 1346 (M + Na) Example 29 FR141579 substance was obtained by reacting FR133303 substance with succinimido 2-(4-octyloxybenzyloxyimino)-acetate according to a similar manner to that of Example 3.

_, IR (Nujol) . 3250, 1650 cm ' FAB-MS e/z = 1270 (M + Na) Example 30 FR141146 substance was obtained by reacting FR133303 substance with 1-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienoyl)-1H-benzotriazole-3-oxide according to a similar manner to that of Example 12.
IR (Nujol) . 3300, 1620, 1040 cm 1 NMR (CD30D, d) . 1.06 (3H, d, J=6.8Hz), 1.19 (3H, d, J=5.9Hz), 1.60 (3H, s), 1.62 (3H, s), 1.66 (3H, s), 1.9-2.2 (11H, m), 2.05 (3H, s), 2.3-2.6 (3H, m), 2.7-2.9 (1H, m), 3.35 (1H, m), 3.7-5.0 (14H, m), 5.08 (4H, m), 5.27 (1H, d, J=2.8Hz), 5.77 (1H, s), 6.86 (1H, d, J=8.3Hz), 7.04 (1H, dd, J=8.3Hz and l.9Hz), 7.32 (1H, d, J=l.9Hz) Example 31 FR140731 substance was obtained by reacting FR133303 substance with 1-(4-octylbenzoyl)-1H-benzotriazole-3-oxide according to a similar manner to that of Example 12.
IR (Nujol) . 3300, 1620, 1040 cm 1 NMR (CD30D, d) . 0.86 (3H, t, J=6.8Hz), 1.06 (3H, d, J=6.8Hz), 1.21 (3H, d, J=5.8Hz), 1.25-1.45 (lOH, m), 1.55-1.75 (2H, m), 1.9-2.25 (3H, m), 2.35-2.6 (3H, m), 2.65 (2H, t, J=7.5Hz), 2.81 (1H, m), 3.32 (1H, m), 3.7-4.8 (14H, m), 4.98 (1H, d, J=3Hz), 5.09 (1H, d, J=3.9Hz), 5.31 (1H, d, J=3Hz), 6.86 (1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2Hz), 7.24 (2H, d, J=8.2Hz), 7.33 (1H, d, J=2Hz), 7.74 (2H, d, J=8.2Hz) FAB-MS e/z = 1197 (M + Na) Example 32 FR140217 substance was obtained by reacting FR133303 substance with 1-f_4-(4-octyloxy)phenoxy]benzoyl-1H-benzotriazole-3-oxide accflrding to a similar manner to that of Example 12.
IR (Nujol) . 3300, 1620 cm 1 F.'~B-MS e/z = 1305 (M + Na) Example 33 FR142472 substance was obtained by reacting FR133303 substance with 1-[4-(4-octyloxyphenyl)benzoyl]-1H-benzotriazole-3-oxide according to a similar manner to ' that of Exam lp a 12.
IR (Nujol) . 3300, 1620 cm 1 NMR (CD30D, d) . 0.88 (3H, t, J=6.7Hz), 1.06 (3H, d, J=6.8Hz), 1.23 (3H, d, J=6.lHz), 1.3-1.6 (lOH, m), 1.8-1.9 (2H, m), 1.9-2.3 (3H, m), 2.3-2.7 (3H, m), 2.9-3.0 (1H, m), 3.39 (1H, m), 3.7-4.7 (16H, m), 4.99 (1H, d, J=3.OHz), 5.10 (1H, d, J=3.7Hz), 5.35 (1H, d, J=2.7Hz), 6.87 (1H, d, J=8.3Hz), 6.99 (2H, d, J=8.8Hz), 7.04 (1H, dd, J=8.3Hz and l.9Hz), 7.33 (1H, d, J=l.9Hz), 7.58 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.4Hz), 7.87 (2H, d, J=8.4Hz) FAB-MS e/z = 1289 (M + Na) Example 34 FR140496 substance was obtained by reacting FR133303 substance with 1-(6-butoxy-2-naphthoyl)-1H-benzotriazole-3-oxide according to a similar manner to that of Example _12.
IR (Nujol) . 3300, 1624 cm 1 FAB-MS e/z = 1207 (M + Na) Example 35 FR140497 substance was obtained by reacting FR133303 substance with 1-(6-hexyloxy-2-naphthoyl)-1H-. benzotriazole-3-oxide according to a similar manner to.
that of Example 12.
IR (Nujol) . 3300, 1620 cm 1 NMR (DMSO-d6 + D20, d) . 0.89 (3H, t, J=6.6Hz), 0.97 ~5 (3H, d, J=6.9Hz), 1.08 (3H, d, J=5.9Hz), 1.2-1.6 .. (6H, m), 1.7-2.1 (5H, m), 2.1-2.5 (3H, m), 2.5-2.7 (1H, m), 3.19 (1H, m), 3.73 (2H, m), :.
3.8-4.5 (12H, m), 4.80 (1H, d, J=3Hz), 4.88 (1H, d, J=3.8Hz), 5.08 (1H, d, J=3Hz),~6.74 (1H, d, 1Q. J=8.2Hz), 6.80 (1H, dd, J=8.2Hz and 2Hz), 7.08 ..-- . (1H, d, J=2Hz), 7.26 (1H, dd, J=8.9Hz and 2.4Hz), 7.39 (1H, d, J=2.4Hz), 7.85 (1H, d, . -J=8.7Hz), 7.89 (1H, d, J=8.7Hz), 7.93 (1H, d, J=8.9Hz), 8.44 (1H, s) 15 FAB-MS e/z = 1236 (M + Na) -.
Example 36 -__;____ _-__ FR143483 substance was obtained by reacting FR133303 _ substance with 1-[6-(2-ethylhexyloxy)-2-naphthoyl]-xH-:.: -.
20 benzotriazole-3-oxide according to a similar manner:to:.=._-._:-- -v._..
that of Example 12. _:
IR (Nujol) . 3250, 1620 cm 1 -NMR (CD30D, d) . 0.93 (3H, t, J=7.4Hz), 0.98 (3H; t;=...-_. J=7.4Hz), 1.06 (3H, d, J=6.8Hz), 1.24 (3H, d, : ...._.
25 J=6.OHz), 1.3-1.7 (8H, m), 1:7-1.9 (1H, m), _....
1.9-2.3 (3H, m), 2.3-2.7 (3H, m), 2.8-3.0 (1H, _.. ..
m), 3.39 (1H, m), 3.7-4.7 (16H, m), 5.00 (1H, d, :.:.
J=4.4Hz), 5.11 (1H, d, J=3.7Hz), 5.37 (1H, d, - .-.:
J=2.6Hz), 6.87 (1H, d, J=8.3Hz), 7.04 (1H, dd, .,:-_._ 30 J=8.3Hz and 2Hz), 7.17 (1H, dd, J=8.9Hz and ..-.._ l.9Hz), 7.22 (1H, d, J=2Hz), 7.33 (1H, d, -.
_.. J=l.9Hz), 7.7-7.9 (3H, m), 8.29 (1H, s) . _.-:.
FAB-MS e/z = 1263 (M + Na) - ._. _ - _.

_ ~g _ 2~4~'~~~~
Example 37 FR140728 substance was obtained by reacting FR133303 substance with 1-(6-decyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide according to a similar manner tn that of Example 12. _ IR (Nujol) . 3300, 1620 cm 1 NMR (DMSO-d6 + D20, d) . 0.86 (3H, t, J=6.6Hz), 0.97 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.2-1.6 (14H, m), 1.7-2.1 (5H, m), 2.1-2.5 (3H, m), ..
2.5-2.7 (1H, m), 3.19 (1H, m), 3.45 (1H, m), 3.73 (2H, m), 3.9-4.5 (12H, m), 4.79 (1H, d, J=3Hz), 4.87 (1H, d, J=3.8Hz), 5.07 (1H, d, J=3Hz), 6.74 (1H, d, J=8.2Hz), 6.79 (1H, dd, J=8.lHz and 2Hz), 7.06 (1H, d, J=2Hz), 7.23 (1H;-L5 dd, J=8.9Hz and 2.4Hz), 7.38 (1H, d, J=2.4Hz), 7.85 (1H, d, J=8.7Hz), 7.89 (1H, d, J=8.7Hz), ~..
7.93 (1H, d, J=8.9Hz), 8.45 (1H, s) FAB-MS 2/z = 1291 (M + Na) ZO Example 3 8 .....: _: _. . _...._ .
FR142172 substance was obtained by reacting FR133303 --substance with 1-[6-(3,7-dimethyloctyloxy)-2-naphthoyl]- -- _ 1H-benzotriazole-3-oxide according to a similar manner to.. _ that of Example 12. ~ __-~___,-_ 25 IR (Nujol) . 3300, 1610 cm 1 : :_ ~_ NMR (DMSO-d6 + D20, d) . 0.85 (6H, d, J=6.6Hz), 0.95.:._ (3H, d, J=5.9Hz), 0.97 (3H, d, J=6.7Hz), 1.08 :..
(3H, d, J=5.9Hz), 1.1-1.4 (6H, m), 1.4-2.1 (7H, .-_ m), 2.1-2.5 (3H, m), 2.5-2.7 (1H, m), 3.19 (1H, 30 m), 3.74 (2H, m), 3.9-4.6 (12H, m), 4.81 (1H, d~
J=3Hz), 4.87 (1H, d, J=3.8Hz), 5.07 (1H, d, r J=3Hz), 6.74 (1H, d, J=8.2Hz), 6.83 (1H, dd, . _._._ - J=8.lHz and 2Hz), 7.06 (1H, d, J=2Hz), 7.23 (lH;r=
_. .. dd, J=8.9Hz and 2.4Hz), 7.40 (1H, d, J=2.4Hz), ..
3:5 7.85 (1H, d, J=8.7Hz), 7.89 (1H, d, J=8.7Hz), ~. -.

2~~~'~~~
7.93 (1H, d, J=8.9Hz), 8.45 (1H, s) FAB-MS e/z = 1291 (M + Na) Example 39 FR143326 substance was obtained by reacting FR133303 substance with 1-[6-(3,7-dimethyl-6-octenyloxy)-2-naphthoyl]-1H-benzotriazole-3-oxide according to a similar manner to that of Example 12.
IR (Nujol) . 3300, 1620, 1260, 1040 cm ~' NMR (CD30D, 8) . 1.00 (3H, d, J=6.2Hz), 1.06 (3H; d,..
J=6.8Hz), 1.25 (3H, d, J=5.9Hz), 1.2-1.6 (ZH, m), 1.6I (3H, s), 1.67 (3H, s), 1.63-2.3 (8H, m), 2.3-2.7 (3H, m), 2.8-3.0 (1H, m), 3.39 (1H, - m), 3.7-4.8 (16H, m), 5.00 (1H, d, J=5.lHz), -.
1.5 5.08-5.2 (2H, ml. 5.37 (1H, d, J=2.5Hz), 6.87 --(1H, d, J=8.3Hz), 7.04 (1H, d, 3=8.3Hz), 7.15 (1H, d, J=8.9Hz), 7.21 (1H, s), 7.33 (1H, s), 7.71 (1H, d, J=8.7Hz), 7.77-7.85 (2H, m), 8.28 w _ (1H, s) Example 4 0 _. -: _._.: . - .-. _- .
FR142390 substance was obtained by reacting FR133303 substance with 1-[6-[(E)-3,7-dimethyl-2,6-octadienyloxy~-2-naphthoyl]-1H-benzotriazole-3-oxide according to a w. - -similar manner to that of Example 12 . - , .: . :: w - : .
IR (Nujol) . 3300, 1620 cm 1 _.
NMR (DMSO-d6 + D20, d) . 0.97 (3H, d, J=6.7Hz). i.07 ~~. - .
(3H, d, J=6.OHz), 1.57 (3H, s), 1.61 (3H, s), .. 1.76 (3H, s), 1.8-2.5 (9H, m), 2.5-2.7 (1H, m), 3.19 (1H, m), 3.45 (1H, m), 3.73 (2H, m), ;
_ 3.9-4.6 (11H, m), 4.70 (2H, d, J=6.5Hz), 4.80 . -. - (1H, d, J=3Hz), 4.87 (1H, d, J=3.8Hz), 5.07 (2H, _ ... -.: m), 5.51 (1H, t, J=6.5Hz), 6.74 (1H, d, :.-_ _ ._. ..:: _. J=8.3Hz), 6.83 (1H, dd, J=8.3Hz and 2Hz), 7.07 - 35 -- :. (1H, d, J=2Hz), 7.24 (1H, dd, J=8.9Hz and _.

- loo -~~4~~r4 2.4Hz), 7.40 (1H, d, J=2.4Hz), 7.8-8.0 (3H, m), 8.45 (1H, s) FAg-MS e/z = 1287 (M + Na) Example 41 FR140729 substance was obtained by reacting FR133303 substance with 1-(6-dodecyloxy-2-naphthoyl)-1H-benzotriazole-3-oxide according to a similar manner to that of Exam 1~. _ _ IR (Nujol) . 3300, 1610 cm 1 NMR (DMSO-d6 + D20, d) . 0.85 (3H, t, J=6.6Hz), 0.97 . (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.2-1.6 (18H, m), 1.7-2.1 (5H, m), 2.1-2.5 (3H, m), 2.5-2.7 (1H, m), 3.19 (1H, m), 3.45 (1H, m), :, , 3.73 (2H, m), 3.9-4.5 (12H, m), 4.79 (1H, d, J=3Hz), 4.87 (1H, d, J=3.8Hz), 5.07 (1H, d, J=3Hz), 6.74 (1H, d, J=8.lHz), 6.78 (1H, dd, _ J=8.lHz and 2Hz), 7.06 (1H, d, J=2Hz), 7.23 (lH, - _ dd, J=8.9Hz and 2.4Hz), 7.38 (1H, d, J=2.4Hz), 7.85 (1H, d, J=8.7Hz), 7.89 (1H, d, J=8.7Hz), 7.93 (1H, d, J=8.9Hz), 8.44 (1H, s) FAB-MS e/z = 1320 (M + Na) _ _ Example 42 __:.....;__.__-FR140730 substance was obtained by reacting FR133303~~ _ -:
substance with 1-(2-anthrylcarbonyl)-1H-benzotriazole-.3-__ __~ -..
oxide according to a similar manner to that of Example-22.:_...._ TR (Nujol) . 3300, 1620 cm 1 _- ,v_ FAB-MS e/z = 1185 (M + Na) _ _. - _ Example 43 . _ FR143020 substance was obtained by reacting FR1333.03:: _:-:
-. substance with 1-[2-(4-octyloxyphenyl)acetyl]-1H-_ :~_-_~ _._.
benzotriazole-3-oxide according to a similar manner ao ._:_-..
that of Exam le 12.

- lol -zR (Nujol) . 3300, 1620 cm 1 NMR (CD30D, d) . 0.87 (3H, t, J=6.8Hz), I.0-I.2 (6H, m), 1.2-1.6 (IOH, m), I.6-1.85 (2H, m), 1.85-2.1 (3H, m), 2.3-2.6 (3H, m), 2.7-2.85 (1H, m), 3.32 (1H, m), 3.46 (2H, s), 3.7-4.7 (I6H, m), 5.04 (1H, d, J=3.7Hz), 5.23 (1H, d, J=2.7Hz), 6.75-6.9 (3H, m), 7.01 (1H, d, J=8.3Hz), 7.15 (2H, d, J=8.5Hz), 7.30 (1H, s) FAB-MS e/ z = 1227 ( M + Na ) .._ . : . _ Example 44 .. .___.__ FR143021 substance was obtained by reacting FR133.303 substance with 1-[3-(4-octyloxyghenyl)propionyl]-1H-benzotriazole-3-oxide according to a similar manner ta_._... -:..:
that of Example 12. :
TR (Nujol) . 3300, 1620 cm 1 -_ ________.
FAB-MS 2/z = 1241 (M + Na) .-Example 45 -FR141315 substance was obtained by reacting FR133303 substance with 1-[(E)-3-(4-octyloxyphenyl)acryloyl]-1H- -benzotriazole-3-oxide according to a similar manner to_ - _._ that of Exam lp a 12 . - _ . - : . _ _~_-_ _.
IR (Nujol) . 3300, 1620 cm 1 .-. _ - NMR (DMSO-d6 + D20, d) . 0.86 (3H, t; J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 1.04 (3H, d, J=5.4Hz), 1.2-1.5 -(10H, m), 1.6-2.0 (5H, m), 2.1-2.5 (3H, m), ~.:
2.5-2.6 (1H, m), 3.17 (1H, m), 3.3-4.5 (15H, m), -.
4.79 (1H, d, J=3Hz), 4.86 (1H, d, J=3.8Hz), 5.01 .-(1H, d, J=3Hz), 6.57 (IH, d, J=15.8Hz), 6.74 (1H, d, J=8.2Hz), 6.82 (1H, d, J=8.2Hz), 6.97 .. . -.
(2H, d, J=8.8Hz), 7.09 (1H, s); 7.34 (1H, d, _ J=15.8Hz), 7.52 (2H, d, J=8.8Hz) ---..._ FAB-MS e/z = 1239 (M + Na) _ 20~~'~~~~
Example 46 rFR140105 substance was obtained by reacting FR133303 substance with 1-(04-octyl-N,N-dimethyl-L-tyrosyl)-1H-benzotriazole-3-oxide according to a similar manner to that of Exam le 12. -IR (Nujol) . 3300, 1620 cm 1 NMR ECD30D, 8) . 0.91 (3H, t, J=6.8Hz), 1.06 (3H, d, J=6.8Hz), 1.12 (3H, d, J=6.lHz), 1.33 (lOH, m), 1.74 (2H, m), 1.98 (3H, m), 2.40 d6H, s), 2.3-2.6 (3H, m), 2.8 (2H, m), 2.9-3.1 (1H, m), 3.3-3.5 (2H, m), 3.6-4.7 (16H, m), 5.06 (1H, d, J=3.8Hz), 5.33 (1H, d, J=3Hz), 6.77 (2H, d,-J=8.6Hz), 6.86 (1H, d, J=8.3Hz), 7.03 (1H, dd, J=8.3Hz and 2Hz), 7.07 (2H, d, J=8.6Hz), 7.31 (1H, d, J=2Hz) -Example 47 __.. __- .
FR141564 .substance was obtained by reacting FR13-3303 substance with 4-octyloxyphenylsulfonyl chloride according to a similar manner to that of Example 6. -IR (Nujol) . 3300, 1620 cm 1 ;-NMR (DNlSO-d6 + D20, d) . 0.87 (3H, t, J=6.7Hz), 0.97 (3H, d, J=6.8Hz), 1.04 (3H, d, J=5.7Hz), 1.1-1.5 (lOH, m), 1.6-2.1 (5H, m), 2.45 (3H, m), 2.5-2.7 (1H, m), 3.19 (1H, m), 3.7-4.5 (16H, m), 4.80 (1H, d, J=3Hz), 4.88 (1H, d, J=4Hz), 5.08 (1H, d, J=3Hz), 6.74 (1H, d, J=8.2Hz),~6.82 (1H, d, -J=8.2Hz), 6.84 (2H, d, J=8.7Hz), 7.07 (1H, s), 7.51 (2H, d, J=8.7Hz) FAB-MS e/z = 1249 (M + Na) ~ .
Example 48 __.____~.~__._ FR143170 substance was obtained by reacting FR13-3303 substance wsth _ - _6-octyloxy-2-naphthylsulfonyl chloride----_ ._ 3.5._ according to a similar manner to that of Example -6.~ : __ IR (Nujol) . 3300, 1620 cm ~
NMR (CD30D, d) . 0.29 (3H, d, J=6.OHz), 0.91 (3H, t, J=6.7Hz), 1.07 (3H, d, J=6.9Hz), 1.25-1.6 (lOH, m), 1.7-2.2 (5H, m), 2.2-2.6 (4H, m), 3.37 (1H, m), 3.55-4.65 (17H, rn), 4.97 (1H, m), 5.54 (1H, m), 6r.84 (1H, d, J=8.3Hz), 7.01 (1H, dd, J=8.4Hz and 2Hz), 7.15-7.3 (3H, m), 7.75-8.0 (3H, m), :
8.35 (1H, s) FAB-MS e/z = 1299 (M + Na) Example 49 w To a solution of FR138364 substance obtained in Example 5 (0.24 g) in acetonitrile (5 ml) was added_..-_ p-toluenesulfonic acid (0.132 g) and stirred for -8w hours at-room temperature. The reaction mixture was added to water and the aqueous layer was adjusted to pH 4:5 with .
saturated sodium bicarbonate aqueous solution. The ._ aqueous solution was subjected to column chromatography on Diction HP-20 and eluted with 80~ aqueous methanol..-The.--~ fractions containing the object compound were combinedvand evaporated under reduced pressure to remove methanol: The ..
residue was lyophilized to give FR138912 substance..(a..15.
g).
IR (Nujol) . 3300, 1620 cm 1 =. _.
FAB-MS e/z = 1272 (M + K) ~ _ ._ ..__ - _ Example 50 The mixture of FR138728 substance obtained in Example .:
- 8 (0.15 g) and 1-octyl-1,4-dihydropyridine-4-thione.(-0.031 . - .
- 30_ g) in N,N-dimethylformamide was stirred for 1. 5 -hours . ~ . w under ice-cooling. The reaction mixture was pulverized - -._ .:. _with diethyl ether (50 ml). The precipitate was.filtrated-. --_ and dried over phosphorus pentoxide under reduced:: v_:-_-.. _ pressure. The powder was added to water (300 ml)-.-and=:-:
adjusted to pH 4.5. The aqueous solution was subjected to -column chromatography on Diction HP-20 (50 ml) and-ehuted=: _:::=,-.

.a..: 1.AW.:._. ~... aS.-_..!a.j4C~3...y6:e:-:hS4..'~a.:,wx-,trn.,we .
,_........e.,s,~ ua .v ., _ e..e...n. ... v..............,._....u .....nw >v,.
_ .....:.. ..e r,..d............. .. ...~s..a" .r..a_ua..cwae.~ana~t., with 80~ aqueous methanol. The fractions containing the abject compound were combined and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give FR138960 substance (0.15 g).
IR (Nujol) . 3300, 1620 cm 1 FAB-MS e/z = 1222 (Free M + Na) The following compounds (Examples 51 to 53) were obtained according to a similar manner to that of Example 3.
Example 51 FR138727 substance NMR (CD30D, d) . 0.90 (~3H, t, J=6.8Hz), 1.05 (3H, d, J=6.8Hz), 1.17-1.33 (13H, m), 1.6-1.8 (2H, m), 1.9-2.1 (3H, m), 2.50 (1H, m), 2.75 (1H, dd, J=l6Hz and 4Hz), 3.40 (1H, m), 3.7-3.8 (1H, m), 3.98 (2H, t, J=6.2Hz), 3.9-4.2 (5H, m), 4.3-4.5 (5H, m), 4.5-4.7 (3H, m), 4.97 (1H, d, J=3Hz), 5.06 (1H, s), 5.20 (1H, d, J=3Hz), 5.40 (1H, d, J=3Hz), 6.85 (1H, d, J=8.3Hz), 6.95 (2H, d "
J=8.5Hz), 7.02 (1H, d, J=8.3Hz), 7.30 (1H, d, -J=8.5Hz), 7.44 (1H, s) Example 52 _._ _.~ ____.
FR138912 substance _ --.
IR (Nujol) . 3300, 1620 cm 1 Exarmple 53 _ . . ________ _.
FR138960 substance --IR (Nujol) . 3300, 1620 cm 1 --In the following, the structures of the compounds of E~les 54 and 55 are shown.
HO OH
fiO
H~~ NFi NH-R
-N o ~o. ~o to Viir>
H H
O
II Ofi NaO-S~O ~ /
O HO
Example Compound No. No. R

54 FR144274 ...CO \ ~ ~
O(CH2)sCH

~

55 FR14427I _C ~ ~ ~ ~ O(CH2)5CH3 The following compounds (Examples 54 and 55) were obtained according to a similar manner to that of Example 3.
Example 54 IR (Nujol) . 3300, 1620 cm 1 Anal_ Calcd. for C55H~3N8S022Na 6H20 C : 4$.53, H : 6.29, N : 8.23. S : 2.35 Found C : 48.36, H : 6.34, N : 8.15, S : 2.30 FAB-MS e/z 1275 (M+Na) Example 55 Anal. Calcd. for C54H71N8S023Na 6H20 C : 47.57, H : 6.14, N : 8.22, S : 2.35 Found C : 47_58, H : 6.05, N : 8.18, S . 2.27 FAB-MS e/z = 1277 (M+Na)

Claims (14)

1. A polypeptide compound of the following general formula:
wherein R1 is hydrogen or acyl group, R2 is hydroxy or acyloxy, R3 is hydroxysulfonyloxy, and R4 is hydrogen or carbamoyl, with proviso that R1 is not palmitoyl, when R2 is hydroxy, R3 is hydroxysulfonyloxy and R4 is carbamoyl, and a pharmaceutically acceptable salt thereof.
2. A polypeptide compound of claim 1, which is shown by the following formula:

wherein R1 is as defined in claim 1.
3. A compound of claim 2, wherein R1 is lower alkanoyl which has one or more substituent(s); higher alkanoyl, lower alkenoyl which have one or more substituent(s); higher alkenoyl; lower alkoxycarbonyl; higher alkoxycarbonyl; aryloxycarbonyl;
arylglyoxyloyl; ar(lower)alkoxycarbonyl which has one or more substituent(s); lower alkylsulfonyl; arylsulfonyl which has one or more substituent(s); ar(lower)alkylsulfonyl; or aroyl which has one or more substituent(s).
4. A compound of claim 3, wherein R1 is lower alkanoyl; halo(lower)alkanoyl;
ar(lower)alkanoyl which has 1 to 3 substituent(s) selected from the group consisting of hydroxy, lower alkoxy, higher alkoxy, aryl, amino, protected amino, di(lower)alkylamino, lower alkoxyimino and ar(lower)alkoxyimino which has 1 to 3 higher alkoxy; heterocyclicthio(lower)alkanoyl which has 1 to 3 higher alkyl;
heterocyclic(lower)alkanoyl which has 1 to 3 substituent(s) selected from the group consisting of lower alkoxyimino, higher alkyl, amino and protected amino;
ar(lower)alkoxyimino(lower)alkanoyl which has 1 to 3 higher alkoxy; higher alkanoyl;
ar(lower)alkenoyl which has 1 to 3 higher alkoxy; higher alkenoyl; lower alkoxycarbonyl;
higher alkoxycarbonyl; aryloxycarbonyl;
arylsulfonyl which has 1 to 3 substituent(s) selected from the group consisting of lower alkyl and higher alkoxy; or aroyl which has 1 to 5 substituent(s) selected from the group consisting of halogen, lower alkyl, higher alkyl, carboxy, lower alkoxy which has 1 to 10 halogen, lower alkoxy(lower)alkoxy, ar(lower)alkoxy, higher alkoxy which has 1 to 17 halogen, higher alkenyloxy, aryl which has 1 to 3 higher alkoxy and aryloxy which has 1 to 3 lower alkoxy or higher alkoxy.
5. A compound of claim 4, wherein R1 is lower alkanoyl; halo(lower)alkanoyl;
phenyl(lower)alkanoyl or naphthyl(lower)alkanoyl, each of which has 1 to 3 substituent(s) selected from the group consisting of hydroxy, lower alkoxy, higher alkoxy, phenyl, amino, lower alkoxycarbonylamino, di(lower)alkylamino, lower alkoxyimino and phenyl(lower)alkoxyimino which has 1 to 3 higher alkoxy;
pyridylthio(lower)alkanoyl which has 1 to 3 higher alkyl; imidazolyl(lower)alkanoyl or thiazolyl(lower)alkanoyl, each of which has 1 to 3 substituent(s) selected from the group consisting of lower alkoxyimino, higher alkyl, amino and lower alkoxycarbonylamino;
phenyl(lower)alkoxyimino(lower)alkanoyl which has 1 to 3 higher alkoxy; higher alkanoyl;
phenyl(lower)alkenoyl which has 1 to 3 higher alkoxy; higher alkenoyl; lower alkoxycarbonyl, higher alkoxycaxbonyl; phenoxycarbonyl;
phenylsulfonyl or naphthylsulfonyl, each of which has 1 to 3 substituent(s) selected from the group consisting of lower alkyl and higher alkoxy; or, benzoyl, naphthoyl or anthrylcarbonyl, each of which has 1 to 5 substituent(s) selected from the group consisting of halogen, lower alkyl, higher alkyl, carboxy, lower alkoxy which has 6 to 10 halogen, lower alkoxy(lower)alkoxy, phenyl(lower)alkoxy, higher alkoxy which has 12 to 17 halogen, higher alkenyloxy, phenyl which has 1 to 3 higher alkoxy, and phenoxy which has 1 to 3 lower alkoxy or higher alkoxy.
6. A compound of claim 5, wherein R1 is phenyl(lower)alkenoyl which has 1 to 3 higher alkoxy; or benzoyl, naphthoyl or anthrylcarbonyl, each of which has 1 to 5 substituent(s) selected from the group consisting of halogen, lower alkyl, higher alkyl, carboxy, lower alkoxy which has 6 to 10 halogen, lower alkoxy(lower)alkoxy, phenyl(lower)alkoxy, higher alkoxy which has 12 to 17 halogen, higher alkenyloxy, phenyl which has 1 to 3 higher alkoxy, and phenoxy which has 1 to 3 lower alkoxy or higher alkoxy.
7. A compound of claim 6, wherein R1 is phenyl(lower)alkenoyl which has higher alkoxy;
or benzoyl or naphthoyl, each of which has higher alkoxy, higher alkenyloxy, or phenyl which has higher alkoxy.
8. A compound of claim 7, wherein R1 is benzoyl which has higher alkoxy.
9. A compound of claim 8, wherein R1 is 4-octyloxybenzoyl.
10. A compound of claim 7, wherein R1 is phenyl(lower)alkenoyl which has higher alkoxy;
or naphthoyl which has higher alkoxy or higher alkenyloxy.
11. A process for the preparation of a polypeptide compound of the formula [I]:

wherein R1 is hydrogen or acyl group, R2 is hydroxy or acyloxy, R3 is hydroxysulfonyloxy, and R4 is hydrogen or carbamoyl, with proviso that R1 is not palmitoyl, when R2 is hydroxy, R3 is hydroxysulfonyloxy and R4 is carbamoyl, or a salt thereof, which comprises i) subjecting a compound [II] of the formula or a salt thereof , to elimination reaction of N-acyl group, to give a compound of the formula [Ia] :
or a salt thereof, or ii) subjecting a compound of [Ia] or a salt thereof thus obtained to acylation reaction, to give a compound of the formula [Ib] :
wherein R~ is acyl group exclusive of palmitoyl, ar a salt thereof, or iii) subjecting a compound [Ic] of the formula wherein R~ is ar(lower)alkanoyl which has higher alkoxy and protected amino, or a salt thereof, to elimination reaction of amino protective group, to give a compound [Id] of the formula:
wherein R~ is ar(lower)alkanoyl which has higher alkoxy and amino, or a salt thereof, or iv) reacting a compound of the formula [Ie] :
wherein R~ is halo(lower)alkanoyl, or a salt thereof, with pyridinethione which may have higher alkyl or a salt thereof, to give a compound of the formula [If]:
wherein R~ is pyridylthio(lower)alkanoyl which may have higher alkyl, or a salt thereof, or v) subjecting a compound of the formula [IV] :
wherein R3 and R4 are each as defined above, and R5 is acyl group, or a salt thereof, to acylation reaction, to give a compound of the formula [Ig]:
wherein R3 and R4 are each as defined above, R1f is acyl group, and R2a is acyloxy, or a salt thereof.
12. A pharmaceutical composition which comprises a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient.
13. A compound of claim 1 and a pharmaceutically acceptable salt thereof for use as a medicament.
14. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.
CA002044746A 1990-06-18 1991-06-17 Polypeptide compound and a process for preparation thereof Expired - Lifetime CA2044746C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB909013558A GB9013558D0 (en) 1990-06-18 1990-06-18 New polypeptide compound and a process for preparation thereof
GB9013558.3 1990-06-18
GB909023666A GB9023666D0 (en) 1990-10-31 1990-10-31 Polypeptide compound and a process for preparation thereof
GB9023666.2 1990-10-31
GB919101552A GB9101552D0 (en) 1991-01-24 1991-01-24 New polypeptide compound and a process for preparation thereof
GB9101552.9 1991-01-24

Publications (2)

Publication Number Publication Date
CA2044746A1 CA2044746A1 (en) 1991-12-19
CA2044746C true CA2044746C (en) 2001-08-07

Family

ID=27265144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002044746A Expired - Lifetime CA2044746C (en) 1990-06-18 1991-06-17 Polypeptide compound and a process for preparation thereof

Country Status (20)

Country Link
US (1) US5376634A (en)
EP (2) EP0462531B1 (en)
JP (1) JP3307410B2 (en)
KR (1) KR100199535B1 (en)
CN (1) CN1040541C (en)
AT (1) ATE143671T1 (en)
AU (1) AU651347B2 (en)
CA (1) CA2044746C (en)
DE (1) DE69122432T2 (en)
DK (1) DK0462531T3 (en)
ES (1) ES2093658T3 (en)
FI (1) FI912873A (en)
GR (1) GR3021780T3 (en)
HU (2) HUT58108A (en)
IE (2) IE912046A1 (en)
IL (1) IL98506A (en)
NO (1) NO912347L (en)
OA (1) OA09369A (en)
PT (1) PT98023B (en)
RU (1) RU2108342C1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8925593D0 (en) * 1989-11-13 1990-01-04 Fujisawa Pharmaceutical Co Fr901379 substance and preparation thereof
US5330973A (en) * 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
US5386009A (en) * 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
IE912046A1 (en) 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
US5428009A (en) * 1990-07-16 1995-06-27 Merck & Co., Inc. Lipopeptide derivatives
USH1638H (en) * 1990-11-08 1997-03-04 Furuta; Takahisa Use of the polypeptide compound
US5385884A (en) * 1991-08-27 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US6743777B1 (en) 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
JPH09500103A (en) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド Cyclohexapeptidyl aminoalkyl ether
AU681119B2 (en) * 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
US5516757A (en) * 1994-09-16 1996-05-14 Merck & Co., Inc. Semi-synthetic lipopeptides, compositions containing said lipopeptides, and methods of use
RU2165423C2 (en) * 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Polypeptide compound, method of its synthesis and pharmaceutical composition
US5516756A (en) * 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
ES2162039T3 (en) * 1995-01-26 2001-12-16 Merck & Co Inc NEW ANTIFUNGIC CYCLOHEXAPEPTIDES.
US5646111A (en) * 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5629290A (en) * 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US5618787A (en) * 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5629289A (en) * 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
EP1666587A1 (en) 1996-06-13 2006-06-07 Astellas Pharma Inc. Cyclic lipopeptide acylase
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1999040108A1 (en) 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AR029876A1 (en) * 1998-05-11 2003-07-23 Takeda Pharmaceutical OXIIMINOALCANOYL ACID COMPOUND, PHARMACEUTICAL COMPOSITION AND AGENT TO CONTROL RETINOID-RELATED RECEPTORS THAT UNDERSTAND AND USE
WO2000011023A2 (en) 1998-08-20 2000-03-02 Eli Lilly And Company Ring modified cyclic peptide analogs
ES2272096T3 (en) 1998-12-09 2007-04-16 Eli Lilly And Company PURIFICATION OF CYCLOPEPTIDIC COMPOUNDS OF EQUINOCANDINA.
JP4272359B2 (en) 1999-03-03 2009-06-03 イーライ リリー アンド カンパニー Echinocandin / Carbohydrate Complex
IL145185A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Echinocandin pharmaceutical formulations containing micelle-forming surfactants
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
ATE338060T1 (en) 1999-03-03 2006-09-15 Lilly Co Eli FORMATION AND ANION EXCHANGE OF INNER CRYSTALLINE AMMONIUM SALTS OF ECHINOCANDIN B
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
JP2004524318A (en) * 2001-02-26 2004-08-12 藤沢薬品工業株式会社 Echinocandin derivatives and their pharmaceutical compositions and uses as pharmaceuticals
KR20010098986A (en) * 2001-07-27 2001-11-09 김종군 Liquid heat insulation coat(TEMP-COAT)
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US7459290B1 (en) 2004-03-30 2008-12-02 Iowa State University Research Foundation, Inc. Methods of using functional 30S subunits
WO2010064219A1 (en) 2008-12-04 2010-06-10 Ranbaxy Laboratories Limited Process for the preparation of a novel intermediate for caspofungin
US8927690B2 (en) 2010-09-29 2015-01-06 Shanghai Techwell Biopharmaceutical Co., Ltd. Process for purifying cyclolipopeptide compounds or the salts thereof
JP6000255B2 (en) * 2010-09-30 2016-09-28 上海天偉生物制薬有限公司 Method for purifying cyclic lipopeptide compound or salt thereof
CN102533551B (en) * 2010-12-15 2013-10-09 上海天伟生物制药有限公司 High-yield strain of peptide antibiotic, preparation method and use thereof
CN102618604B (en) * 2011-01-31 2014-09-03 上海天伟生物制药有限公司 Preparation method of cyclic lipopeptide compound
AU2012244435B2 (en) 2011-04-20 2017-06-15 Xellia Pharmaceuticals Aps Method for purification of Micafungin
CN102627688B (en) * 2012-03-30 2014-12-31 上海天伟生物制药有限公司 High purity cyclic peptide compound and preparation method and application thereof
CN102627689B (en) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 Hydrate of cyclopeptide compound as well as preparation method and application thereof
CN102659930B (en) * 2012-03-30 2014-04-23 上海天伟生物制药有限公司 High-purity cyclopeptide crystal and its preparation method and use
CN103387975A (en) 2012-05-11 2013-11-13 上海天伟生物制药有限公司 Immobilized cyclic lipopeptide acyltransferase, preparation method thereof, and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293488A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912B nucleus
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
CA1182812A (en) * 1979-12-13 1985-02-19 Bernard J. Abbott Process for the preparation of derivatives of cyclic peptide nuclei
CA1159450A (en) * 1979-12-13 1983-12-27 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4293484A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912H nucleus
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
EP0209061B1 (en) * 1985-07-17 1994-01-12 Hoechst Aktiengesellschaft Peptides having an anticoagulant activity, process for their preparation, obtention, their use and agents containing them
EP0311193B1 (en) * 1987-10-07 1993-12-01 Merck & Co. Inc. Antifungal fermentation product
DK173802B1 (en) * 1988-09-12 2001-11-05 Merck & Co Inc Preparation for the treatment of Pneumocystis carinii infections and use of a cyclohexapeptide for the preparation of a drug against Pneumocystis carinii infections
WO1991005794A1 (en) * 1989-10-18 1991-05-02 City Of Hope Stable mammalian cell lines that express aromatase
GB8925593D0 (en) * 1989-11-13 1990-01-04 Fujisawa Pharmaceutical Co Fr901379 substance and preparation thereof
US5386009A (en) * 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US5330973A (en) * 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
IE912046A1 (en) 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
EP0486011A3 (en) * 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii

Also Published As

Publication number Publication date
AU651347B2 (en) 1994-07-21
PT98023A (en) 1992-03-31
CN1059729A (en) 1992-03-25
RU2108342C1 (en) 1998-04-10
OA09369A (en) 1992-09-15
JPH04352799A (en) 1992-12-07
ES2093658T3 (en) 1997-01-01
HU912014D0 (en) 1991-12-30
HU211740A9 (en) 1995-12-28
IE912046A1 (en) 1991-12-18
DE69122432D1 (en) 1996-11-07
US5376634A (en) 1994-12-27
IL98506A0 (en) 1992-07-15
IE990233A1 (en) 2000-11-15
FI912873A (en) 1991-12-19
NO912347D0 (en) 1991-06-17
DK0462531T3 (en) 1996-11-18
EP0462531B1 (en) 1996-10-02
JP3307410B2 (en) 2002-07-24
CA2044746A1 (en) 1991-12-19
EP0462531A3 (en) 1992-11-04
KR920000788A (en) 1992-01-29
HUT58108A (en) 1992-01-28
DE69122432T2 (en) 1997-03-20
KR100199535B1 (en) 1999-06-15
PT98023B (en) 1998-11-30
IL98506A (en) 1996-09-12
EP0729974A1 (en) 1996-09-04
FI912873A0 (en) 1991-06-14
EP0462531A2 (en) 1991-12-27
AU7843591A (en) 1992-01-16
ATE143671T1 (en) 1996-10-15
GR3021780T3 (en) 1997-02-28
NO912347L (en) 1991-12-19
CN1040541C (en) 1998-11-04

Similar Documents

Publication Publication Date Title
CA2044746C (en) Polypeptide compound and a process for preparation thereof
US5502033A (en) Antimicrobial polypeptide compound a pharmaceutical composition comprising the same, and a method for treating infectious diseases
EP0486011A2 (en) Pharmaceutical composition against Pneumocystis carinii
KR100346489B1 (en) NOVEL POLYPEPTIDE COMPOUND AND METHOD FOR PRODUCING THE SAME
CA2145826C (en) Lipopeptide derivatives, a process for their preparation and their use
US5369093A (en) Lipopeptide derivatives
JPH08509722A (en) Cyclohexapeptidylamine compound
JPH10508026A (en) Azacyclohexapeptide compound
JPH02134399A (en) Pipecolic acid-containing peptrids, their manufacture and medicine composition
JPH06157594A (en) Preparation of certain phosphate compound of cyclohexapeptide
US6399567B1 (en) Cyclic hexapeptides having antibiotic activity
US6331521B1 (en) Echinocandine derivatives with antimicrobial activity
US20040082757A1 (en) Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs
USH1638H (en) Use of the polypeptide compound
US5952299A (en) Cyclic peptide nuclei and derivatives thereof
EP0031220A1 (en) Derivatives of cyclic peptide nuclei
EP0584360A1 (en) Wf11243 substance
US5348940A (en) Cyclohexapeptidyl hydroxypropionitrile compounds
JP2003505397A (en) N-acyl side chain analogs of pseudomycin
KR100474161B1 (en) Aerothricin derivatives, processes for the preparation of the same and pharmaceutical compositions containing the same
JPH08119983A (en) New compound wf14865, its production and its use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry